Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐☒ No ☒☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~July 31, 2019,~~October 29, 2021, the registrant had ~~124,287,992~~141,131,844 shares of common stock, $0.0001 par value per share, outstanding.

This report contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this report other than statements of historical fact are forward-looking statements, which include but are not limited to, statements about:

The forward-looking statements in this report also include statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management's Discussion and Analysis of Financial Condition and Results of ~~Operations,”~~Operations” and elsewhere in this report and in other documents we file with the Securities and Exchange Commission (“SEC”) from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this report represent our views as of the date of this report.

We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Unless otherwise stated or the context otherwise indicates, references to “we,” “us,” “our” and similar references refer to Adaptive Biotechnologies Corporation.

(in thousands,,except ~~except~~share ~~share~~and ~~and~~per share ~~per share~~amounts)

	June 30,			December 31,
	2019			2018			September 30, 2021			December 31, 2020
	(unaudited)						(unaudited)
Assets
Current assets
Cash and cash equivalents	$	48,458		$	55,030		$	122,401		$	123,436
Short-term marketable securities		374,543			109,988
Short-term marketable securities (amortized cost of $292,556 and $564,036, respectively)								292,639			564,833
Accounts receivable, net		7,252			4,807			17,122			10,047
Inventory		8,004			7,838			18,231			14,063
Prepaid expenses and other current assets		4,044			3,055			16,634			14,535
Total current assets		442,301			180,718			467,027			726,914
Long-term assets
Property and equipment, net		22,298			19,125			87,820			39,692
Restricted cash and other assets		5,040			247
Operating lease right-of-use assets								89,446			99,350
Long-term marketable securities (amortized cost of $217,455 and $118,429, respectively)								217,379			118,525
Restricted cash								2,138			2,138
Intangible assets, net		12,784			13,626			8,955			10,225
Goodwill		118,972			118,972			118,972			118,972
Other assets								870			598
Total assets	$	601,395		$	332,688		$	992,607		$	1,116,414
Liabilities, convertible preferred stock and shareholders’ deficit
Liabilities and shareholders’ equity
Current liabilities
Accounts payable	$	2,944		$	1,793		$	8,252		$	3,237
Accrued liabilities		5,019			2,562			17,034			13,162
Accrued compensation and benefits		4,429			4,641			12,034			11,950
Current portion of deferred rent		1,276			1,109
Current deferred revenue		61,194			12,695
Current portion of operating lease liabilities								5,108			3,529
Current portion of deferred revenue								79,954			73,319
Total current liabilities		74,862			22,800			122,382			105,197
Long-term liabilities
Convertible preferred stock warrant liability		2,602			336
Deferred rent liability, less current portion		5,455			6,102
Operating lease liabilities, less current portion								108,044			104,333
Deferred revenue, less current portion		240,919			704			110,638			163,618
Total liabilities		323,838			29,942			341,064			373,148
Commitments and contingencies (Note 8)
Convertible preferred stock: $0.0001 par value, 93,762,517 shares authorized at June 30, 2019 and December 31, 2018, respectively; 93,039,737 and 92,790,094 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively; aggregate liquidation preference of $574,374 and $572,866 at June 30, 2019 and December 31, 2018, respectively		561,931			560,858
Shareholders’ deficit
Common stock: $0.0001 par value, 131,000,000 shares authorized at June 30, 2019 and December 31, 2018, respectively; 13,725,381 and 12,841,536 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively		1			1
Commitments and contingencies (Note 9)
Shareholders’ equity
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at September 30, 2021 and December 31, 2020; 0 shares issued and outstanding at September 30, 2021 and December 31, 2020								—			—
Common stock: $0.0001 par value, 340,000,000 shares authorized at September 30, 2021 and December 31, 2020; 141,027,487 and 137,646,896 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively								14			14
Additional paid-in capital		46,160			37,902			1,308,946			1,253,971
Accumulated other comprehensive gain (loss)		382			(107	)
Accumulated other comprehensive gain								7			893
Accumulated deficit		(330,917	)		(295,908	)		(657,458	)		(511,612	)
Total shareholders’ deficit		(284,374	)		(258,112	)
Total liabilities, convertible preferred stock and shareholders’ deficit	$	601,395		$	332,688
Total Adaptive Biotechnologies Corporation shareholders’ equity								651,509			743,266
Noncontrolling interest								34			—
Total shareholders’ equity								651,543			743,266
Total liabilities and shareholders’ equity							$	992,607		$	1,116,414

The accompanying notes are an integral part of these condensed consolidated financial statements.

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018			Three Months Ended September 30,						Nine Months Ended September 30,
	(unaudited)												2021			2020			2021			2020
Revenue
Sequencing revenue	$	11,865		$	8,281		$	17,948		$	14,061		$	22,106		$	11,276		$	55,835		$	28,730
Development revenue		10,273			3,287			16,856			7,222			17,361			15,023			60,579			39,467
Total revenue		22,138			11,568			34,804			21,283			39,467			26,299			116,414			68,197
Operating expenses
Cost of revenue		5,734			5,044			10,722			9,033			14,189			6,053			34,945			16,308
Research and development		16,527			9,452			29,010			18,307			36,072			30,314			107,644			80,241
Sales and marketing		8,897			5,329			16,714			10,376			24,949			14,474			68,769			42,813
General and administrative		6,662			4,632			13,666			9,175			20,154			12,079			51,156			36,138
Amortization of intangible assets		423			424			842			843			428			428			1,270			1,275
Total operating expenses		38,243			24,881			70,954			47,734			95,792			63,348			263,784			176,775
Loss from operations		(16,105	)		(13,313	)		(36,150	)		(26,451	)		(56,325	)		(37,049	)		(147,370	)		(108,578	)
Interest and other income, net		446			820			2,105			1,567			327			1,018			1,429			5,805
Income tax (expense) benefit														—			(688	)		—			1,116
Net loss		(15,659	)		(12,493	)		(34,045	)		(24,884	)		(55,998	)		(36,719	)		(145,941	)		(101,657	)
Fair value adjustment to Series E-1 convertible preferred stock options		(710	)		(2	)		(964	)		2
Net loss attributable to common shareholders	$	(16,369	)	$	(12,495	)	$	(35,009	)	$	(24,882	)
Net loss per share attributable to common shareholders, basic and diluted	$	(1.23	)	$	(1.01	)	$	(2.68	)	$	(2.02	)
Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted		13,279,324			12,385,888			13,074,692			12,334,227
Add: Net loss attributable to noncontrolling interest														95			—			95			—
Net loss attributable to Adaptive Biotechnologies Corporation													$	(55,903	)	$	(36,719	)	$	(145,846	)	$	(101,657	)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted													$	(0.40	)	$	(0.27	)	$	(1.04	)	$	(0.79	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted														140,833,564			134,372,026			140,060,379			129,289,948

The accompanying notes are an integral part of these condensed consolidated financial statements.

Condensed Consolidated Statements of ~~Convertible Preferred Stockand~~Shareholders’ ~~Deficit~~Equity

Convertible
preferred stock

Common stock

Additional
paid-in

Accumulated
other
comprehensive

Accumulated

Total
shareholders’

Shares

Amount

Shares

Amount

capital

(loss) income

deficit

deficit

Balance as of March 31, 2018 (unaudited)

92,745,734

$
561,396

12,301,844

$
1

$
28,620

$
(283
)

$
(261,950
)

$
(233,612
)
Issuance of common stock for cash upon exercise of stock options (unaudited)

—

—

245,000

—

415

—

—

415

Issuance of Series E-1 convertible preferred stock for cash upon
   exercise of Series E-1 convertible preferred stock options at fair value (unaudited)

44,360

35

—

—

—

—

—

—

Vested Series E-1 convertible preferred stock option forfeitures (unaudited)

—

(767
)

—

—

476

—

291

767

Series E-1 convertible preferred stock option share-based compensation (unaudited)

—

—

—

—

1

—

—

1

Adjustment to redemption value for vested Series E-1 convertible
   preferred stock options (unaudited)

—

1

—

—

(1
)

—

—

(1
)
Change in redemption value for vested Series E-1 convertible
   preferred stock options (unaudited)

—

2

—

—

—

—

(2
)

(2
)
Common stock option share-based compensation (unaudited)

—

—

—

—

2,447

—

—

2,447

Other comprehensive income (unaudited)

—

—

—

—

—

43

—

43

Net loss (unaudited)

—

—

—

—

—

—

(12,493
)

(12,493
)
Balance as of June 30, 2018 (unaudited)

92,790,094

$
560,667

12,546,844

$
1

$
31,958

$
(240
)

$
(274,154
)

$
(242,435
)

Balance as of March 31, 2019 (unaudited)

93,023,694

$
561,210

12,930,536

$
1

$
40,981

$
92

$
(314,548
)

$
(273,474
)
Issuance of common stock for cash upon exercise of stock options (unaudited)

—

—

794,845

—

1,847

—

—

1,847

Issuance of Series E-1 convertible preferred stock for cash upon
   exercise of Series E-1 convertible preferred stock options at fair value (unaudited)

16,043

11

—

—

—

—

—

—

Change in redemption value for vested Series E-1 convertible
   preferred stock options (unaudited)

—

710

—

—

—

—

(710
)

(710
)
Common stock option share-based compensation (unaudited)

—

—

—

—

3,332

—

—

3,332

Other comprehensive income (unaudited)

—

—

—

—

—

290

—

290

Net loss (unaudited)

—

—

—

—

—

—

(15,659
)

(15,659
)
Balance as of June 30, 2019 (unaudited)

93,039,737

$
561,931

13,725,381

$
1

$
46,160

$
382

$
(330,917
)

$
(284,374
)

~~CondensedStatements of Convertible Preferred StockandShareholders’Deficit (Continued)~~

Balance as of December 31, 2017

92,656,029

$
561,333

12,208,731

$
1

$
24,972

$
(166
)

$
(249,423
)

$
(224,616
)
Adjustments to accumulated deficit for adoption of guidance on accounting for share-based payment transactions (unaudited)

—

—

—

—

140

—

(140
)

—

Issuance of common stock for cash upon exercise of stock options (unaudited)

—

—

338,113

—

823

—

—

823

Issuance of Series E-1 convertible preferred stock for cash upon
   exercise of Series E-1 convertible preferred stock options at fair value (unaudited)

134,065

100

—

—

—

—

—

—

Vested Series E-1 convertible preferred stock option forfeitures (unaudited)

—

(767
)

—

—

476

—

291

767

Series E-1 convertible preferred stock option share-based compensation (unaudited)

—

—

—

—

3

—

—

3

Adjustment to redemption value for vested Series E-1 convertible
   preferred stock options (unaudited)

—

3

—

—

(3
)

—

—

(3
)
Change in redemption value for vested Series E-1 convertible
   preferred stock options (unaudited)

—

(2
)

—

—

—

—

2

2

Common stock option share-based compensation (unaudited)

—

—

—

—

5,547

—

—

5,547

Other comprehensive loss (unaudited)

—

—

—

—

—

(74
)

—

(74
)
Net loss (unaudited)

—

—

—

—

—

—

(24,884
)

(24,884
)
Balance as of June 30, 2018 (unaudited)

92,790,094

$
560,667

12,546,844

$
1

$
31,958

$
(240
)

$
(274,154
)

$
(242,435
)

Balance as of December 31, 2018

92,790,094

$
560,858

12,841,536

$
1

$
37,902

$
(107
)

$
(295,908
)

$
(258,112
)
Issuance of common stock for cash upon exercise of stock options (unaudited)

—

—

883,845

—

1,880

—

—

1,880

Issuance of Series E-1 convertible preferred stock for cash upon
   exercise of Series E-1 convertible preferred stock options at fair value (unaudited)

249,643

109

—

—

—

—

—

—

Change in redemption value for vested Series E-1 convertible
   preferred stock options (unaudited)

—

964

—

—

—

—

(964
)

(964
)
Common stock option share-based compensation (unaudited)

—

—

—

—

6,378

—

—

6,378

Other comprehensive income (unaudited)

—

—

—

—

—

489

—

489

Net loss (unaudited)

—

—

—

—

—

—

(34,045
)

(34,045
)
Balance as of June 30, 2019 (unaudited)

93,039,737

$
561,931

13,725,381

$
1

$
46,160

$
382

$
(330,917
)

$
(284,374
)

	Common Stock				Additional		Accumulated Other			Accumulated			Noncontrolling			Total
	Shares		Amount		Paid-In Capital		Comprehensive Gain			Deficit			Interest			Shareholders’ Equity
Balance at June 30, 2020		128,233,842	$	12	$	958,097	$	2,153		$	(430,323	)	$	—		$	529,939
Issuance of common stock upon public offering, after deducting underwriters' discounts and net offering costs payable by us		7,200,000		1		271,838		—			—			—			271,839
Issuance of common stock for cash upon exercise of stock options		958,414		—		4,244		—			—			—			4,244
Common stock option and restricted stock unit share-based compensation		—		—		6,470		—			—			—			6,470
Other comprehensive loss		—		—		—		(726	)		—			—			(726	)
Net loss		—		—		—		—			(36,719	)		—			(36,719	)
Balance at September 30, 2020		136,392,256	$	13	$	1,240,649	$	1,427		$	(467,042	)	$	—		$	775,047

Balance at June 30, 2021		140,663,755	$	14	$	1,294,506	$	216		$	(601,555	)	$	129		$	693,310
Issuance of common stock for cash upon exercise of stock options		360,607		—		2,797		—			—			—			2,797
Vesting of restricted stock units		3,125		—		—		—			—			—			—
Common stock option and restricted stock unit share-based compensation		—		—		11,643		—			—			—			11,643
Other comprehensive loss		—		—		—		(209	)		—			—			(209	)
Net loss		—		—		—		—			(55,903	)		(95	)		(55,998	)
Balance at September 30, 2021		141,027,487	$	14	$	1,308,946	$	7		$	(657,458	)	$	34		$	651,543

The accompanying notes are an integral part of these condensed consolidated financial statements.

	Common Stock				Additional		Accumulated Other			Accumulated			Noncontrolling			Total
	Shares		Amount		Paid-In Capital		Comprehensive Gain			Deficit			Interest			Shareholders’ Equity
Balance at December 31, 2019		125,238,142	$	12	$	935,834	$	671		$	(365,478	)	$	—		$	571,039
Issuance of common stock upon public offering, after deducting underwriters' discounts and net offering costs payable by us		7,200,000		1		271,838		—			—			—			271,839
Adjustments to accumulated deficit for adoption of guidance on accounting for leases		—		—		—		—			93			—			93
Issuance of common stock for cash upon exercise of stock options		3,949,614		—		15,459		—			—			—			15,459
Vesting of restricted stock units		4,500		—		—		—			—			—			—
Common stock option and restricted stock unit share-based compensation		—		—		17,518		—			—			—			17,518
Other comprehensive income		—		—		—		756			—			—			756
Net loss		—		—		—		—			(101,657	)		—			(101,657	)
Balance at September 30, 2020		136,392,256	$	13	$	1,240,649	$	1,427		$	(467,042	)	$	—		$	775,047

Balance at December 31, 2020		137,646,896	$	14	$	1,253,971	$	893		$	(511,612	)	$	—		$	743,266
Issuance of common stock upon exercise of common stock warrant		54,162		—		—		—			—			—			—
Issuance of common stock for cash upon exercise of stock options		3,310,804		—		23,299		—			—			—			23,299
Vesting of restricted stock units		15,625		—		—		—			—			—			—
Common stock option and restricted stock unit share-based compensation		—		—		31,376		—			—			—			31,376
Capital contributions for Spin Technologies, Inc.		—		—		300		—			—			129			429
Other comprehensive loss		—		—		—		(886	)		—			—			(886	)
Net loss		—		—		—		—			(145,846	)		(95	)		(145,941	)
Balance at September 30, 2021		141,027,487	$	14	$	1,308,946	$	7		$	(657,458	)	$	34		$	651,543

Theaccompanying notesareanintegralpartofthese condensed consolidated financial statements.

	Six Months Ended June 30,
	2019			2018			Nine Months Ended September 30,
	(unaudited)						2021			2020
Operating activities
Net loss	$	(34,045	)	$	(24,884	)	$	(145,941	)	$	(101,657	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		2,811			2,099			7,834			4,845
Noncash lease expense								5,259			2,217
Share-based compensation expense		6,378			5,550			31,376			17,518
Intangible assets amortization		842			843			1,270			1,275
Investment amortization		(1,896	)		(459	)		5,956			(484	)
Gain on equipment disposals		(79	)		(41	)
Fair value adjustment of convertible preferred stock warrant		2,266			—
Benefit from income tax								—			(1,116	)
Other		1			3			(9	)		62
Changes in operating assets and liabilities:
Accounts receivable, net		(2,445	)		1,165			(7,075	)		802
Inventory		(166	)		(2,921	)		(4,168	)		(1,667	)
Prepaid expenses and other current assets		(883	)		(364	)		(2,239	)		(3,886	)
Accounts payable and accrued liabilities		1,314			(1,013	)		5,518			30
Deferred rent		(480	)		(359	)
Operating lease liabilities								9,935			(282	)
Deferred revenue		288,714			5,425			(46,345	)		(27,281	)
Other		1			(207	)		(272	)		(215	)
Net cash provided by (used in) operating activities		262,333			(15,163	)
Net cash used in operating activities								(138,901	)		(109,839	)
Investing activities
Purchases of property and equipment		(5,354	)		(1,614	)		(52,501	)		(9,433	)
Proceeds from sales of equipment		—			19
Purchases of marketable securities		(358,671	)		(110,947	)		(238,001	)		(299,786	)
Proceeds from maturities of marketable securities		96,500			80,516
Net cash used in investing activities		(267,525	)		(32,026	)
Proceeds from sales and maturities of marketable securities								404,500			532,224
Net cash provided by investing activities								113,998			223,005
Financing activities
Proceeds from exercise of stock options		1,989			923			23,439			15,495
Payment of deferred initial public offering costs		(3,360	)		—
Other		(9	)		(10	)
Net cash (used in) provided by financing activities		(1,380	)		913
Net decrease in cash, cash equivalents and restricted cash		(6,572	)		(46,276	)
Proceeds from public offering of common stock, net of underwriting discounts and commissions								—			272,160
Payment of public offering costs, net								—			(321	)
Proceeds from initial capital contributions for Spin Technologies, Inc.								429			—
Net cash provided by financing activities								23,868			287,334
Net (decrease) increase in cash, cash equivalents and restricted cash								(1,035	)		400,500
Cash, cash equivalents and restricted cash at beginning of year		55,091			85,366			125,574			98,714
Cash, cash equivalents and restricted cash at end of period	$	48,519		$	39,090		$	124,539		$	499,214
Noncash investing and financing activities
Purchases of equipment included in accounts payable and accrued liabilities	$	1,490		$	535		$	8,133		$	3,582
Deferred offering costs included in accounts payable and accrued expenses	$	1,433		$	—
Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases							$	—		$	36,607

The accompanying notes are an integral part of these condensed consolidated financial statements.

Adaptive Biotechnologies Corporation (“we,” “us” or “our”) is a commercial-stage company advancing the field of ~~immune-driven~~immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and aims to understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database, which is ~~the foundation for our expanding suite of~~underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and ~~services. The cornerstone~~services that we are tailoring to each individual patient. We have commercial products and services and a robust pipeline of ~~our immune medicine platform~~clinical products and ~~core immunosequencing product, immunoSEQ, serves~~services that we are designing to diagnose, monitor and enable the treatment of diseases, such as ~~our underlying research~~cancer, autoimmune conditions and development engine and generates revenue from academic and biopharmaceutical customers. Our first clinical diagnostic product, clonoSEQ, is the first test authorized by the Food and Drug Administration (“FDA”) for the detection and monitoring of minimal residual disease (“MRD”) in patients with select blood cancers.infectious diseases.

We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington.

~~Our registration statement on Form S-1 related~~In 2021, we formed a corporate subsidiary, Spin Technologies, Inc. (“SpinTech”), to facilitate the development of a potential new early-stage sequencing technology that is ancillary to our ~~initial public offering (“IPO”) was declared effective on June 26, 2019,~~core business. We have a 70% ownership interest in SpinTech. All intercompany transactions and ~~our common stock began trading on the Nasdaq Global Select Market on June 27, 2019. On July 1, 2019, we completed our IPO~~balances between us and this majority-owned subsidiary have been eliminated in which we issued and sold 17,250,000 shares of common stock, including shares issued upon the exercise in full of the underwriters’ over-allotment option, at a public offering price of $20.00. We received approximately $316.0 million in net proceeds, after deducting underwriting discounts and commission of approximately $24.2 million and offering expenses of approximately $4.8 million.

~~Immediately prior to the completion~~consolidation. The remaining interest, held by certain of our ~~IPO on July 1, 2019, 93,039,737 shares of convertible preferred stock then outstanding converted into an equivalent number of shares of common stock. On July 1, 2019,~~related parties and related family trusts, was reported as noncontrolling interest in ~~connection with the closing of~~ our IPO, our amended and restated articles of incorporation, as filed with the Secretary of State of the State of Washington, and our amended and restated bylaws became effective. Also on July 1, 2019, we adopted a new equity incentive plan (“2019 Plan”), establishing an initial reserve of 15,519,170 shares under the 2019 Plan.

~~The~~unaudited condensed consolidated financial ~~statements as of June 30, 2019, including share and per share amounts, do not give effect to our IPO as it closed subsequent to June 30, 2019.~~statements.

The preparation of financial statements in conformity with ~~U.S.~~accounting principles generally accepted ~~accounting principles~~in the United States of America (“GAAP”) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, ~~including the fair value of stock, and~~ the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.

In our opinion, the accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state the financial position and the results of our operations and cash flows for interim periods in accordance with GAAP. All such adjustments were of a normal, recurring nature. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with our audited financial statements and notes included in our ~~prospectus dated June 26, 2019~~Annual Report on Form 10-K for the year ended December 31, 2020 filed with the ~~Securities~~SEC on February 24, 2021.

We are required to maintain certain balances under lease arrangements for some of our property and ~~Exchange Commission (“SEC”) on June 27, 2019 in connection with our IPO (“Prospectus”).~~

facility leases. We had restricted cash of $2.1 million as of September 30, 2021 and December 31, 2020.

We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and ~~cash equivalents~~warehouse facilities that we occupy, as well as server space. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are ~~stated~~recognized at ~~fair value. Cash equivalents~~the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of the new lease standard.

Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only ~~securities having an original maturity~~when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.

We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the balance sheet a lease that has a lease term of ~~three~~twelve months or less ~~at the time of purchase. We limit our credit risk associated with cash~~ and ~~cash equivalents by placing our investments with banks~~does not contain a purchase option that we ~~believe~~ are ~~highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist~~reasonably certain to exercise.

Lease expense is recognized on a straight-line basis over the terms of ~~bank deposits and investments in money market funds,~~the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as ~~well as highly liquid U.S. government debt and agency securities and commercial paper with original maturities~~adjustments to lease expense on a straight-line basis over the terms of ~~three months or less.~~the leases.

We are subject to a concentration of risk from a limited number of suppliers, or in some cases single suppliers, for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock.

Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, United States (“U.S.”) government debt securities, U.S. government agency ~~bonds,~~securities, commercial paper and corporate bonds with high-quality accredited financial institutions.

Significant customers are those ~~which~~that represent more than 10% of our total revenue or accounts receivable, ~~balance at~~net balances for the periods and as of each ~~respective~~ balance sheet ~~date.~~date presented, respectively. Revenue from these customers reflects their purchase of our products and services and ~~we do not believe their loss would have a material adverse effect on~~ our ~~business.~~collaboration efforts with Genentech.

For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows:

We recognize revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606 (“ASC 606”), Revenue from Contracts with Customers. Under ASC 606, for all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: ~~(i)~~(1) identify the contract or contracts; ~~(ii)~~(2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; ~~(iii)~~(3) measure the transaction price, including the constraint on variable consideration; ~~(iv)~~(4) allocate the transaction price to the performance obligations based on estimated selling prices; and ~~(v)~~(5) recognize revenue when (or as) we satisfy each performance obligation. The following is a summary of the application of the respective model to each of our revenue classifications.

Our revenue is generated from immunosequencing (“sequencing”) products and services (“sequencing revenue”) and from regulatory or development support services leveraging our immune medicine platform (“development revenue”). When revenue generating contracts have elements of both sequencing revenue and development revenue, we ~~allocate~~classify revenue based on the nature of the performance obligation and the allocated transaction price.

Sequencing revenue reflects the amounts generated from providing testing services through clonoSEQ to clinical and research customers, from providing our T-Detect COVID test to clinical customers and from providing sequencing services ~~and testing~~ through ~~our~~ immunoSEQ ~~and clonoSEQ products and services~~ to ~~our~~ research ~~and clinical customers, respectively.~~

For research customers, contracts typically include an amount billed in advance of services (“upfront”), and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified two typical performance obligations under the terms of our

~~research service contracts: sequencing services and related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer.~~

For other research customers who choose to purchase a research use only kit, the kits are sold on a price per kit basis with amounts payable upon delivery of the kit. Payments received are recorded as deferred revenue. For these customers, we have identified one performance obligation: the delivery of sample results. We recognize revenue as the results are delivered to the customer based on a proportion of the estimated samples that can be reported on for each kit.customers.

For clinical customers, we primarily derive ~~revenues~~revenue from providing our clonoSEQ ~~test~~ report to ordering ~~physicians, and we bill and receive payments from commercial third-party payors and medical institutions.~~physicians. In these transactions, we have identified one performance ~~obligation:~~obligation, the delivery of a clonoSEQ ~~report.~~report, and we bill and receive payments from medical institutions and commercial and government third-party payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted as necessary based on actual collection experience.

~~In January 2019,~~For our clonoSEQ ~~received~~coverage under Medicare, coverage aligned with the FDA label and National Comprehensive Cancer Network (“NCCN”) guidelines for longitudinal monitoring in multiple myeloma (“MM”) and B cell acute lymphoblastic leukemia (“ALL”). Wewe bill ~~Medicare for~~ an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient’s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue ~~is recognized~~recognition commences at the time the initial billable test result is delivered and is based upon cumulative tests delivered to date. ~~For~~We estimate the ~~three and six months ended June 30, 2019,~~number of tests we ~~recognized $0.3 million and $0.8 million relating~~expect to ~~the coverage policy, respectively; $0.1 million and $0.4 million of this revenue was related~~deliver over a patient’s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to ~~tests delivered in periods prior to the three and six months ended June 30, 2019, respectively.~~change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient’s treatment ~~cycle.~~cycle or when the likelihood becomes remote that a patient will receive additional testing.

For research customers, contracts typically include an amount billed in advance of services (“upfront”) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified 2 typical performance obligations under the terms of our research service contracts: sequencing services and related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the remaining samples expected to be delivered.

We derive revenue by providing services through development agreements to biopharmaceutical customers who seek access to our immune medicine platform technologies. We generate revenues from the delivery of professional support activities pertaining to the use of ~~our proprietary~~ immunoSEQ and ~~clonoSEQ services~~our minimal residual disease (“MRD”) product in the development of the respective customers’ initiatives. The transaction price for these contracts may consist of a combination of non-refundable upfront fees, separately priced sequencing fees, ~~progress based~~progress-based milestones and regulatory milestones. The development agreements ~~may~~ include single or multiple performance obligations, depending on the contract. For certain contracts, we ~~may~~ perform services to support the biopharmaceutical customers’ regulatory ~~submission~~submissions as part of their registrational trials. These services may include regulatory support pertaining to our technology intended to be utilized as part of the submission, development of analytical plans for our sequencing data, participation on joint research committees and assistance in completing a regulatory submission. Generally, these services are not distinct within the context of the contract and they are accounted for as a single performance obligation.

When sequencing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional sequencing services is not considered part of the contract. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. Variable consideration related to ~~progress based~~progress-based and regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue recognized will not occur. Progress milestones, such as the first sample result delivered or final patient enrollment in a customer trial, are customer dependent and are included in the transaction price when the respective milestone is probable of occurring. Milestone payments that are not within our customers’ control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate ~~the~~ scientific, clinical, regulatory and other risks, ~~that must be managed,~~ as well as the level of effort and investment required to achieve the respective milestone.

The primary method used to estimate standalone selling price for performance obligations is the adjusted market assessment approach. Using this approach, we evaluate the market in which we sell our services and estimate the price that a customer in that market would be willing to pay for our services. We recognize revenue using either an input or output measure of progress that faithfully depicts performance on a contract, depending on the contract. The measure used is dependent on the nature of the service to be provided in each contract. Selecting the measure of progress and estimating progress to date requires significant judgment.

~~Deferred offering costs consist~~During the three months ended September 30, 2021, we executed an intellectual property license agreement that includes variable consideration related to sales-based royalties. Any consideration related to such royalties will be recognized as development revenue at the later of ~~fees and expenses incurred in connection with~~when (i) the ~~anticipated sale~~related sales occur or (ii) the performance obligation to which some or all of ~~our common stock in~~ the IPO, including the legal, accounting, printing and other IPO-related costs. Deferred offering costs of $4.8 million are capitalized and classified within restricted cash and other assets on the condensed balance sheet as of June 30, 2019.sales-based royalty has been allocated has been satisfied (or partially satisfied).

Net LossPer ShareAttributableto Adaptive Biotechnologies Corporation CommonShareholders

We calculate our basic and diluted net loss per share attributable to common shareholders in conformity with the two-class method required for companies with participating securities. We consider our convertible preferred stock to be participating securities. In the event a dividend is declared or paid on common stock, holders of convertible preferred stock are entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders ~~is calculated~~ by dividing ~~the~~ net loss attributable to ~~common shareholders~~Adaptive Biotechnologies Corporation by the weighted-average number of shares of common stock outstanding for the period. ~~Net loss attributable to common shareholders is determined by allocating undistributed earnings between common and preferred shareholders.~~ The diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. The net loss attributable to common shareholders was not allocated to the convertible preferred stock under the two-class method as the convertible preferred stock does not have a contractual obligation to share in our losses. For purposes of this calculation, ~~convertible preferred~~common stock warrants, stock options and ~~warrants to purchase common~~nonvested restricted stock ~~or convertible preferred stock~~units are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as their effect is anti-dilutive.

~~In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09,~~ ~~Compensation—Stock Compensation~~ (Topic 718), intended to simplify the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statements of cash flows. This guidance also allowed for an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. We adopted this guidance as of January 1, 2018 and elected to account for forfeitures as they occur. We utilized a modified retrospective transition method, recorded the cumulative impact of applying this guidance, and recognized a cumulative increase to additional paid-in capital and an increase to accumulated deficit of $0.1 million.

~~In January 2017, the FASB issued ASU No. 2017-04,~~ ~~Intangibles—Goodwill and Other~~ ~~(Topic 350):~~ ~~Simplifying the Test for Goodwill Impairment~~, intended to simplify the goodwill impairment test. Under the new guidance, goodwill impairment is measured by the amount by which the carrying value of a reporting unit exceeds its fair value, without exceeding the carrying amount of goodwill allocated to that reporting unit. This guidance is effective January 1, 2022 and is required to be adopted on a prospective basis, with early adoption permitted. We adopted this guidance as of January 1, 2018 and the adoption did not have any impact on our financial statements.

~~In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation~~ ~~(Topic 718):~~ ~~Improvements to Nonemployee Share-Based Payment Accounting~~, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance is effective for us beginning in 2019, with early adoption permitted. We adopted the guidance effective January 1, 2019 and the adoption did not have any impact on our financial statements.

~~In February 2016, the FASB issued ASU No. 2016-02,~~ ~~Leases~~ (Topic 842), intended to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheets and disclosing key information about leasing arrangements. This guidance is effective for us in fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Although we are currently evaluating the impact that adopting this guidance will have on our financial statements, we believe the most significant changes will be related to the recognition of the right-of-use assets and related lease liabilities related to our operating leases on the balance sheets.

~~In June 2016, the FASB issued ASU 2016-13,~~ ~~Financial Instruments—Credit Losses~~ ~~(Topic 326):~~ ~~Measurement of Credit Losses on Financial Instruments~~, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. The guidance is effective for us beginning in 2020, with early adoption permitted. Although we are currently evaluating the impact that adopting this guidance prospectively will have on our financial statements, we do not expect the adoption to have a material impact on our financial statements.

~~In August 2018, the FASB issued ASU No. 2018-15,~~ ~~Intangibles—Goodwill and Other: Internal-Use Software~~ (Subtopic 350-40), to provide additional guidance on the accounting for costs of implementation activities performed in a cloud computing arrangement. This guidance is effective for fiscal years beginning after December 15, 2019 and early adoption of the amendments in this update are permitted. We do not expect the adoption of this guidance to have a material impact on our financial statements.

On December 18, 2015, we entered into a translational development agreement with a biopharmaceutical customer for access to certain of our oncology immunosequencing research datasets, including full-time employee support, to accelerate the customer’s preclinical, nonclinical and clinical trial testing. Under the initial terms of the agreement we could be entitled to up to $40.0 million over a period of four years which does not include any separately negotiated research sequencing contracts. If the biopharmaceutical customer terminates the agreement prior to the end of the initial four-year research term for any reason other than a material uncured breach by us, then the biopharmaceutical partner has agreed to pay us $0.8 million. In May 2019, the agreement was subsequently amended to reduce the services provided, which in turn reduced the fourth year of eligible payments to $2.3 million.

We identified one performance obligation under this agreement, as the services were determined to be highly interrelated. We determined that any separately negotiated sequencing contracts are not performance obligations under the contract, as the contract did not contain any material rights related to such sequencing contracts. For the identified performance obligation, we assessed the work to be performed over the duration of the contract and determined that it is a consistent level of support throughout the period, and therefore revenue has been recognized straight-line over the contract term.

Revenue recognized from this translational development agreement, excluding separately negotiated research sequencing contracts, was $1.1 million and $2.5 million in the three months ended June 30, 2019 and 2018, respectively, and $1.1 million and $5.0 million in the six months ended June 30, 2019 and 2018, respectively.

In 2017, we entered into an agreement with a customer to provide services to accelerate its research initiatives. We identified one performance obligation under the agreement, as the services were determined to be highly interrelated. We determined that any separately negotiated sequencing contracts are not performance obligations under the contract, as the contract did not contain any material rights related to such sequencing contracts. Revenue recognized from this agreement, excluding sequencing revenue, was $0.1 million and $0.2 million in the three months ended June 30, 2019 and 2018, respectively, and $0.2 million and $0.3 million in the six months ended June 30, 2019 and 2018, respectively.

~~In 2017 and 2018, we~~We have entered into agreements with biopharmaceutical customers to further develop and commercialize ~~clonoSEQ~~our MRD product and the biopharmaceutical customers’ therapeutics. Under each of the agreements, we received or will receive non-refundable upfront payments and could receive substantial additional payments upon reaching certain ~~progress~~progress-based milestones or ~~achievement of~~achieving certain regulatory milestones pertaining to the customers’ ~~therapeutic~~therapeutics and our ~~clonoSEQ test.~~MRD product.

Under the contracts, we identify performance obligations, which may include: ~~(i)~~(1) obligations to provide services supporting the customer’s regulatory submission activities as they relate to our ~~clonoSEQ test;~~MRD product; and ~~(ii)~~(2) sequencing services ~~for~~related to customer-provided samples for their regulatory submissions. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated immunosequencing services. At contract inception, we fully ~~constrained~~constrain any consideration related to ~~the~~ regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers’ own submission decision-making. We recognize revenue ~~relating~~related to the sequencing services as sequencing revenue over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, ~~and~~ when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort ~~completed using a cost-based model.~~completed.

We recognized ~~$0.5~~$3.2 million in revenue during the nine months ended September 30, 2021 due to changes in estimates of total samples to be provided under certain of our MRD development agreements for which we had previously received upfront consideration, of which $0.3 million was recognized as development revenue in the respective period.

We earned $1.5 million and ~~$0.6~~$10.0 million during the three and nine months ended September 30, 2021, respectively, and $2.5 million during the three and nine months ended September 30, 2020 upon the achievement of certain regulatory milestones by our respective customers’ therapeutics. We recognized these earnings as development revenue within the respective periods, as we determined that the amounts were consistent with our estimated standalone selling prices and the respective performance obligations were complete.

In total, we recognized $1.9 million and $11.4 million in development revenue related to ~~these contracts in~~our MRD development agreements during the three and nine months ended ~~June~~September 30, ~~2019 and 2018,~~2021, respectively, and ~~$0.8~~$2.6 million and ~~$1.9~~$3.1 million in development revenue related to our MRD development agreements during the ~~six~~three and nine months ended ~~June~~September 30, ~~2019 and 2018,~~2020, respectively.

As of ~~June~~September 30, ~~2019,~~2021, in future periods we could receive up to an additional ~~$115.0~~$333.5 million in milestone payments if certain regulatory approvals are obtained by our customers’ therapeutics in connection with MRD data generated from our ~~clonoSEQ test.~~MRD product.

In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (“Genentech Agreement”~~) with Genentech, Inc. (“Genentech”~~) to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable, upfront payment of $300.0 million in February 2019 and may be eligible to receive more than $1.8 billion over time, including payments of up to $75.0 million upon the achievement of specified regulatory milestones, up to $300.0 million upon the achievement of specified development milestones and up to $1,430.0 million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the agreement, we are pursuing two product development pathways for novel T cell immunotherapies in which Genentech intends to use T cell receptors (“TCRs”) screened by our immune medicine platform to engineer and manufacture cellular medicines:

Under the terms of the agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in ASC Topic 808, Collaborative Arrangements (“ASC 808”), because both parties are active participants in the activity and are exposed to significant risks and rewards depending on the activity’s commercial failure or success. Because ASC 808 does not provide guidance on how to account for the activities under a collaborative arrangement, we applied the guidance in ASC 606 to account for the activities related to the Genentech ~~collaboration.~~Agreement.

In applying ASC 606, we identified the following performance obligations at the inception of the agreement:

We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech’s control of product commercialization. Specifically, under the agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other, as opposed to both. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway.

Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for ~~patient specific~~patient-specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty ~~as a result of~~resulting from the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties.

We determined the initial transaction price shall be made up of only the $300.0 million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal asgiven their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the transaction price as of ~~June~~September 30, ~~2019.~~2021. We excluded the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur.

As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared ~~Product~~Products and Personalized Product pathways. When any of the potential regulatory and development milestones are no longer fully constrained and included in the transaction price, such amounts will be recognized using the cumulative catch-up method based on proportional performance at such time. We currently expect to recognize the revenue over a period of approximately seven to eight years from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared ~~Product~~Products and the Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known.

We recognized revenue of ~~approximately $8.5~~$15.0 million and ~~$14.8~~$12.3 million ~~for~~during the three ~~and six~~ months ended ~~June~~September 30, ~~2019,~~2021 and 2020, respectively, and $47.8 million and $35.9 million during the nine months ended September 30, 2021 and 2020, respectively, related to the Genentech ~~collaboration.~~Agreement. Costs related to the Genentech ~~collaboration~~Agreement are included in research and development expenses.

The following ~~table sets~~tables set forth the fair value of financial assets as of September 30, 2021 and ~~liabilities~~December 31, 2020 that were measured at fair value on a recurring basis (in thousands):

June 30, 2019

Level 1

Level 2

Level 3

Total

(unaudited)

Financial assets

Money market funds

$
35,695

$
—

$
—

$
35,695

Commercial paper

—

88,161

—

88,161

U.S. government debt and agency securities

—

273,713

—

273,713

Corporate bonds

—

22,661

—

22,661

Total financial assets

$
35,695

$
384,535

$
—

$
420,230

Financial liabilities

Convertible preferred stock warrant liability

$
—

$
—

$
2,602

$
2,602

Total financial liabilities

$
—

$
—

$
2,602

$
2,602

	September 30, 2021
	Level 1		Level 2		Level 3		Total
Financial assets
Money market funds	$	113,486	$	—	$	—	$	113,486
U.S. government debt securities		—		482,044		—		482,044
Corporate bonds		—		27,974		—		27,974
Total financial assets	$	113,486	$	510,018	$	—	$	623,504

December 31, 2018

Level 1

Level 2

Level 3

Total

Financial assets

Money market funds

$
45,998

$
—

$
—

$
45,998

Commercial paper

—

16,887

—

16,887

U.S. government debt and agency securities

—

85,623

—

85,623

Corporate bonds

—

7,478

—

7,478

Total financial assets

$
45,998

$
109,988

$
—

$
155,986

Financial liabilities

Convertible preferred stock warrant liability

$
—

$
—

$
336

$
336

Total financial liabilities

$
—

$
—

$
336

$
336

	December 31, 2020
	Level 1		Level 2		Level 3		Total
Financial assets
Money market funds	$	103,283	$	—	$	—	$	103,283
U.S. government debt securities		—		671,777		—		671,777
Corporate bonds		—		11,581		—		11,581
Total financial assets	$	103,283	$	683,358	$	—	$	786,641

Level 1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level 2 securities consist of U.S. government debt securities ~~U.S. government agency bonds, commercial paper~~ and corporate bonds, and are valued based on recent trades of securities in inactive markets or ~~based~~ on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. Of the Level 2 commercial paper and U.S. government debt and agency securities balances, $6.0 million and $4.0 million, respectively, is recorded as cash and cash equivalents. Level 3 liabilities that are measured at fair value on a recurring basis consist of a convertible preferred stock warrant liability. During the six months ended June 30, 2019, we recognized $2.3 million of expense related

Notesto ~~the revaluation of the convertible preferred stock warrant liability in interest and other income, net.~~Unaudited Condensed Consolidated Financial Statements (Continued)

~~The fair value of the convertible preferred stock warrant liability is estimated using the Black-Scholes option-pricing model. Certain inputs were utilized in the option-pricing model as follows:~~(unaudited)

Available-for-sale investments consisted of the following as of ~~June~~September 30, ~~2019~~2021 and December 31, ~~2018~~2020 (in thousands):

~~AdaptiveBiotechnologiesCorporation~~All the U.S. government debt securities and corporate bonds designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective balance sheet date.

~~Notesto Unaudited Condensed Financial Statements (Continued)~~Accrued interest receivable is excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivable of $2.0 million and $2.5 million were presented separately within the prepaid expenses and other current assets line item on our unaudited condensed consolidated balance sheet as of September 30, 2021 and on our condensed consolidated balance sheet as of December 31, 2020, respectively.

The following table presents the gross unrealized holding losses and fair value for investments in an unrealized loss position, and the length of time ~~that~~ individual securities have been in a continuous loss position, as of ~~June~~September 30, ~~2019~~2021 (in thousands):

We ~~evaluated~~periodically review our ~~securities for other-than-temporary impairment and considered the decline in market value for the~~available-for-sale securities to ~~be primarily attributable~~assess for credit impairment. Some of the factors considered in assessing impairment include the extent to ~~current economic~~which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market ~~conditions. It is~~data.

As of September 30, 2021, we did not intend, nor were we more likely than not ~~that we will~~to be required, to sell ~~the securities, and we do not intend to do so prior to~~our available-for-sale investments before the recovery of ~~the~~their amortized cost ~~basis.~~basis, which may be maturity. Based on ~~this analysis, these marketable securities were not considered~~our assessment, we concluded all impairment as of September 30, 2021 to be ~~other-than-temporarily impaired~~due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment of ~~June 30, 2019.~~our available-for-sale securities was recorded in other comprehensive loss.

~~All the corporate debt, U.S. government and agency securities and commercial paper have an effective maturity date of less than one year.~~16

There have been no0 changes in the carrying amount of goodwill since its recognition in 2015.

Intangible assets subject to amortization as of ~~the dates presented~~September 30, 2021 and December 31, 2020 consisted of the following (in thousands):

The developed technology was acquired in connection with our acquisition of Sequenta, Inc. ~~(“Sequenta”)~~ in 2015. The remaining balance of the acquired technology and the purchased intellectual property is expected to be amortized over the next ~~approximately 7.5~~5.3 years.

As of ~~June~~September 30, ~~2019,~~2021, expected future amortization expense for intangible assets was as follows (in thousands) ~~(unaudited)~~:

Deferred revenue by revenue classification as of September 30, 2021 and December 31, 2020 was as follows (in thousands):

Deferred revenue from our Genentech ~~deferred revenue~~Agreement represents ~~$45.0~~$57.5 million and ~~$240.2~~$106.7 million of the current and non-current development deferred revenue balances, respectively, ~~at June~~as of September 30, ~~2019.~~2021 and $55.1 million and $157.0 million of the current and non-current development deferred revenue balances, respectively, as of December 31, 2020. In general, we expect that the current amounts will be recognized as revenue within 12 months and the ~~long-term~~non-current amounts will be recognized as revenue over a period of approximately ~~seven~~five to ~~eight years.~~six years from September 30, 2021. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on the various development activities.

~~Changes in deferred revenue during the six months ended June 30, 2019 were as follows (in thousands):~~

As of June 30, 2019, $4.4 million was recognized that was included in the deferred revenue balance at December 31, 2018. As a result of cancelled customer sequencing contracts, we recognized $0.8 million of sequencing revenue during the six months ended June 30, 2019.

~~We have entered into various non-cancelable lease agreements for our office and laboratory spaces.~~

In July 2011, we entered into a non-cancelable lease agreement with a minority shareholder for laboratory and office space in Seattle, Washington. The lease terms were subsequently amended multiple times, most recently in June 2016. The lease terminates in June 2023. The lease also requires us to pay additional amounts for operating and maintenance expenses.

In October 2016, we entered into an agreement to sublease certain laboratory and office space in South San Francisco, California. The lease commenced in October 2016 and terminated in March 2019. The lease required us to pay additional amounts for operating and maintenance expenses.

In April 2018, we entered into a lease agreement to lease additional space in South San Francisco, California. The lease term is through March 2026 and provides for one five-year option. We will be responsible for our share of allocable operating expenses, tax expenses and utilities cost during the duration of the lease term. In connection with the lease, the landlord funded agreed-upon improvements prior to the lease commencement date of December 12, 2018. The landlord was solely responsible for the $2.4 million cost of such improvements, which we recognized as a leasehold improvement asset that depreciates beginning from the commencement date to the initial lease term, and a corresponding leasehold incentive obligation, which is amortized over the life of the lease.

During the nine months ended September 30, 2021, we recognized $3.4 million in revenue as a result of ~~June~~changes in estimates of total samples to be provided under certain of our agreements and cancelled biopharmaceutical customer sequencing contracts for which we had received upfront consideration. Additionally, we recognized $1.4 million and $2.0 million of sequencing revenue during the three and nine months ended September 30, ~~2019, future minimum lease payments, exclusive~~2021, respectively, related to Medicare reimbursements resulting from our determination that the likelihood of ~~operating~~additional testing for specific patients was remote and ~~maintenance costs,~~a change in our estimate of expected cumulative tests per patient for one of our covered indications.

Changes in deferred revenue during the nine months ended September 30, 2021 were as follows (in thousands) ~~(unaudited)~~:

As of September 30, 2021, $36.7 million was recognized as revenue that was included in the deferred revenue balance at December 31, 2020.

We have operating lease agreements for laboratory and office facilities in Seattle, Washington, South San Francisco, California and New York City, New York, as well as server space. Additionally, in March 2021, we executed a lease to rent approximately 27,000 square feet of a warehouse in Bothell, Washington, which we classified as an operating lease upon commencement during the nine months ended September 30, 2021. Rent obligations commenced in October 2021 and the lease expires 120 months thereafter, subject to an early termination option after the seventh year and an option to twice extend the lease for five years. Furthermore, the landlord agreed to fund $1.2 million in improvements in connection with this lease. For the nine months ended September 30, 2021, ROU assets obtained in exchange for operating lease liabilities was $5.4 million.

As of September 30, 2021, we were not party to any finance leases. Our leases have remaining terms of 0.6 years to 11.9 years and include options to extend certain of the leases for up to 10.0 years and terminate certain of the leases after as few as 3.0 years. We adjust lease terms for these options only when it is reasonably certain we will exercise these options. As of September 30, 2021, it was reasonably certain that we would exercise our option to terminate 2 of our leases after 3.0 years.

We previously entered into a $2.1 million letter of credit with one of our financial institutions in connection with one of our leases.

Other information related to our operating leases as of September 30, 2021 was as follows:

The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities as of ~~operating and maintenance costs, were $1.1~~September 30, 2021 (in thousands):

Operating lease expense was $3.1 million and ~~$0.9~~$1.4 million for the three months ended ~~June~~ September 30, ~~2019~~2021 and ~~2018,~~2020, respectively, and $9.3 million and $3.7 million for the nine months ended September 30, 2021 and 2020, respectively. Variable lease expense for operating leases was $0.8 million and $0.7 million for the three months ended September 30, 2021 and 2020, respectively, and $2.3 million and $1.8 million for the ~~six~~nine months ended ~~June~~September 30, ~~2019~~2021 and ~~2018,~~2020, respectively.

Cash paid for amounts included in the measurement of lease liabilities was $5.6 million and cash received for tenant improvement allowances was $11.5 million during the nine months ended September 30, 2021. Cash paid during the nine months ended September 30, 2020 for amounts included in the measurement of lease liabilities was $1.8 million, net of $1.8 million of cash received for tenant improvement allowances.

We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We ~~are~~were not ~~currently~~ party to any material legal ~~proceedings.~~proceedings as of September 30, 2021.

In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our ~~Board~~board of ~~Directors~~directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims.

~~Convertible preferred stock at June 30, 2019 consisted of the following (in thousands, except share data) (unaudited):~~

~~(1) Includes vested Series E-1 convertible preferred stock options of $0.7 million which are not included in the shares issued and outstanding.~~

We are authorized to issue ~~131,000,000~~10,000,000 shares of preferred stock, par value $0.0001 per share. As of September 30, 2021, 0 shares of preferred stock were outstanding.

We are authorized to issue 340,000,000 shares of common stock. Our common stock has a par value of $0.0001 per share, no preferences or privileges and is not redeemable. Holders of our common stock are entitled to ~~one~~1 vote for each share of common stock held. The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time. As of September 30, 2021, we had 141,027,487 shares of common stock outstanding.

WeAs of September 30, 2021, we have reserved shares of common stock for the ~~following as of June 30, 2019 (unaudited):~~following:

Our 2019 Equity Incentive Plan (“2019 Plan”) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.

Furthermore, our Employee Stock Purchase Plan (“ESPP”) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) 1% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.

Effective January 1, 2021, our 2019 Plan reserve increased by 6,882,344 shares. Our board of directors determined not to increase the ESPP reserve in 2021.

In ~~connection with two transactions in 2012 and 2013,~~2014, we granted warrants to purchase up to 55,032 shares of common stock. The warrants are exercisable at any time for a period of ten years from the date of issuance at a weighted-average exercise price of $0.37, except in the case ofissued a warrant to purchase ~~20,000~~56,875 shares of ~~common~~Series C convertible preferred stock at an exercise price of ~~$0.45 per share that would have expired if unexercised~~$2.64. The warrant was exercisable for a period of seven years from the date of issuance. Immediately prior to and in connection with the ~~closing~~completion of our ~~IPO.~~

initial public offering on July 1, 2019, this convertible preferred stock warrant was converted to a warrant to purchase the same number of shares of common stock. The warrant was exercised on February 25, 2021 through a cashless exercise, resulting in the issuance of 54,162 shares of our common stock. The impact of this cashless exercise was immaterial to our unaudited condensed consolidated financial statements. As of September 30, 2021, there were 0 outstanding warrants to purchase common stock.

We adopted an equity incentive plan in 2009 (“2009 Plan”) that ~~provides~~provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the option exercise price for incentive and nonqualified stock options ~~may~~were not to be less than the fair market value of our common stock at the date of grant. Options granted under this plan expire no later than ten years from the grant date and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While 0 shares are available for future issuance under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder.

The 2019 Plan became effective immediately prior to the closing of our initial public offering in July 2019. The 2019 Plan provides for the issuance of awards in the form of options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the option exercise price per share shall not be less than the fair market value of a share of stock on the effective date of grant, as ~~determined~~defined by ~~our Board~~the 2019 Plan, unless explicitly qualified under the provisions of ~~Directors. Options~~Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, options granted under this plan expire no later than ten years from the grant date and vesting is established at the time of grant. Except for certain option and restricted stock unit grants made to non-employee directors, stock options and restricted stock units granted under the 2019 Plan generally vest over a four-year period, subject to continuous service through each applicable vesting date. As of ~~June~~September 30, ~~2019,~~2021, we have ~~20,837,404~~authorized 29,118,513 shares of common stock ~~available~~ for issuance under the ~~2009~~2019 Plan.

~~A summary of our option activity~~Changes in shares available for grant during the ~~six~~nine months ended ~~June~~September 30, ~~2019 is~~2021 were as follows:

In connection with our acquisition of Sequenta in January 2015, we assumed Sequenta’s Equity Incentive Plan (“2008 Plan”), including all outstanding options and shares available for future issuanceNotesto Unaudited Condensed Consolidated Financial Statements (Continued)

Stock option activity under the ~~2008~~2009 Plan ~~which are all~~and 2019 Plan during the nine months ended September 30, 2021 was as follows:

The weighted-average remaining contractual life for options outstanding as of September 30, 2021 was 7.1 years. The weighted-average remaining contractual life for vested and exercisable options as of September 30, 2021 was 5.9 years.

As of September 30, 2021, $0.1 million was included in the prepaid expenses and other current assets line item on our unaudited condensed consolidated balance sheet for ~~Series E-1 convertible preferred stock.~~unsettled cash proceeds related to options exercised during the nine months ended September 30, 2021. Of the $23.4 million proceeds from exercise of stock options included on our unaudited condensed consolidated statements of cash flows for the nine months ended September 30, 2021, $0.3 million related to options exercised prior to but settled during the nine months ended September 30, 2021. Of the $15.5 million proceeds from exercise of stock options included on our unaudited condensed consolidated statements of cash flows for the nine months ended September 30, 2020, $0.5 million related to options exercised prior to but settled during the nine months ended September 30, 2020. Furthermore, as of September 30, 2020, there was $0.4 million in unsettled cash proceeds related to options exercised during the nine months ended September 30, 2020.

Restricted stock unit activity under the 2019 Plan during the nine months ended September 30, 2021 was as follows:

The estimated grant date fair value of options granted during the nine months ended September 30, 2021 and 2020 was estimated using the Black-Scholes option-pricing model with the following assumptions:

The weighted-average volatility used in the grant date fair value calculation of options granted during the nine months ended September 30, 2021 and 2020 was 68.6% and 71.2%, respectively.

~~A summary of our Series E-1 convertible preferred stock option activity during the six months ended June 30, 2019 is as follows:~~

The estimated fair value of options granted during the six months ended June 30, 2019 and 2018 was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions for our 2009 Plan:

The determination of the grant date fair value of stock options ~~on the date of grant~~ using a Black-Scholes option-pricing model is affected by the ~~estimated~~ fair value of our common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows:

Fair value of common stock—The grant date fair value of our common stock has been determined by our Board of Directors with input from management. The grant date fair value of the common stock was determined using valuation methodologies which utilize certain assumptions, including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability (Level 3 inputs). In determining the fair value of the common stock, the methodologies used to estimate the enterprise value were performed using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. For valuations after the closing of our IPO, our board of directors plans to determine the fair value of each share of common stock is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.

Expected term—The expected ~~life~~term of options granted to employees and non-employee directors is determined using the “simplified” method, as illustrated in ASC Topic 718, Compensation—Stock Compensation, as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is ~~presumed to be~~based on the ~~average~~midpoint between the vesting date and the end of ~~the weighted-average vesting term and~~ the contractual term of the option.

Risk-free interest rate—We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected ~~term~~terms of the options.

Expected volatility—As we do not have sufficient trading history for our common stock, the expected volatility is based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of ~~the~~ expected term.

Expected dividend yield—We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of ~~zero~~0 in the option valuation model.

~~AdaptiveBiotechnologiesCorporation~~The grant date fair value of restricted stock units granted is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.

Share-based compensation expense of $3.3 million and $2.4 million was recognized during the three months ended June 30, 2019 and 2018, respectively, and $6.4 million and $5.6 million was recognized during the six months ended June 30, 2019 and 2018, respectively. The compensation costs related to stock options and restricted stock units for the three and nine months ended September 30, 2021 and 2020, respectively, are included inon our unaudited condensed consolidated statements of operations as follows (in thousands):

~~At June~~As of September 30, ~~2019,~~2021, unrecognized share-based compensation expense related to unvested stock options was ~~$33.2~~$97.6 million, which is expected to be recognized over a remaining weighted-average period of ~~3.16~~2.9 years. Additionally, as of September 30, 2021, unrecognized share-based compensation expense related to unvested restricted stock units was $30.3 million, which is expected to be recognized over a remaining weighted-average period of 3.4 years.

The following table sets forth the computation of the basic and diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the three and nine months ended September 30, 2021 and 2020, respectively (in thousands, except ~~shares~~share and per share amounts):

Since we were in a loss position for all periods presented, basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is the same as diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the ~~periods presented,~~three and nine months ended September 30, 2021 and 2020, respectively, as they had an anti-dilutive effect:

On July 1, 2019, we completed our IPO. For details regarding this event, including the automatic conversion of all shares of our convertible preferred stock into common stock, our amended and restated articles of incorporation and bylaws and our 2019 Plan, please refer to Note 1 – Organization and Description of Business – Initial Public Offering.

In August 2019, we entered into an operating lease to rent 100,000 square feet in a to-be-constructed building in Seattle, Washington. Shell construction is expected to be completed in 2020. The lease term commences on the date that the landlord delivers the premises to us for construction of certain tenant improvements. Rent obligations commence 10 months thereafter, and the lease term ends 142 months form the date rent commences, subject to our option to twice extend the lease for five years. The lease is cancellable under certain circumstances if the landlord fails to deliver the premises to us by May 1, 2021. We plan to occupy the new building in 2021, once interior construction is finished. The lease also requires us to pay additional amounts for operating and maintenance expenses. In connection with the new lease, we also entered into a letter of credit of $2.1 million with one of our existing financial institutions.

Furthermore, in August 2019, we amended the lease for our current headquarters in Seattle, Washington to expand the size of the existing premises by approximately 8,400 square feet. Rent obligations of the expanded premises commence four months after the landlord delivers the premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends 142 months after the commencement date of the new lease mentioned above, subject to our option to twice extend the lease for five years. If the new lease does not commence, the lease term for the existing premises and the expanded premises ends March 31, 2024.

Expected future minimum payments for the leased spaces, exclusive of operating and maintenance costs and assuming attainment of our target commencement dates, are as follows (in thousands) (unaudited):

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes and the other financial information appearing elsewhere in this report, as well as the other financial information we file with the SEC from time to time. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and ~~uncertainties.~~ uncertainties relating to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements.

As a result of many factors, including those factors set forth in the “Risk Factors” section of this report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

We are advancing the field of ~~immune-driven~~immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and aims to understand precisely how itthe immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that we are tailoring to each individual patient. We have ~~two~~ commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases, such as cancer, autoimmune conditions and infectious diseases.

Our immune medicine platform is the foundation for our expanding suite of products and services. The cornerstone of our platform and core immunosequencing product, immunoSEQ, serves as our underlying research and development engine and generates revenue from ~~academic~~biopharmaceutical and ~~biopharmaceutical~~academic customers. Our first clinical diagnostic product, clonoSEQ, is the first test authorized by the ~~FDA~~Food and Drug Administration for the detection and monitoring of MRD in patients with MMmultiple myeloma (“MM”), B cell acute lymphoblastic leukemia (“ALL”) and ~~ALL~~chronic lymphocytic leukemia (“CLL”), and is ~~being validated~~also available as a CLIA-validated laboratory developed test for patients with other ~~blood~~lymphoid cancers. Leveraging our collaboration with Microsoft to create the TCR-Antigen Map, we are also developing a diagnostic product, immunoSEQ Dx, that may enable early detection of many diseases from a single blood test. Our therapeutic product candidates, being developed under the Genentech Agreement, leverage our platform to identify specific immune cells to develop into cellular therapies in oncology.

Since our inception, we have devoted a majority of our resources to research and development activities to develop our immune medicine platform.

We are using the TCR-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. T-Detect COVID, for which we have received emergency use authorization, confirms past SARS-CoV-2 infection, the virus that causes COVID-19, and is also the first indication for the T-Detect product line. We expect to launch T-Detect Lyme during the 2022 Lyme season, have discovered signals in both ileal Crohn’s and multiple sclerosis and continue to pursue signals for other disease states, including in autoimmune disease.

Our therapeutic product candidates, being developed under the Genentech Agreement, leverage our platform ~~which enables the delivery of~~to identify specific receptors on immune cells to develop into cellular therapies in oncology. We also extended our ~~products~~platform to identify highly potent neutralizing antibodies against SARS-CoV-2 and ~~services for life sciences research, clinical diagnostics and drug discovery customers.~~we believe this differentiated approach may be leveraged across multiple disease states.

For our life ~~science~~sciences research customers, we provide two categories of products and services using ~~immunoSEQ, our core sequencing and immunomics tracking technology.~~immunoSEQ. First, we provide immunosequencing services, the revenue from which we record as sequencing revenue. Second, we provide certain research customers professional support, for which we receive nonrefundable upfront or recurring payments. We may receive additional payments upon those customers achieving specified milestones. ~~We record~~Revenue related to these ~~support~~ activities are recorded as development revenue.

For our clinical diagnostics customers, we sell our clonoSEQ diagnostic ~~tests,~~test and T-Detect COVID test, which include our immunosequencing services and are thus recorded as sequencing revenue. In the future, we intend to sell other ~~diagnostics~~diagnostic products and services, including other indications for T-Detect, which we also expect to record as sequencing revenue.

For our current drug discovery collaborator, Genentech, we screen, identify and characterize TCRs in support of our collaboration. We record revenue from this collaboration as development revenue.

Historically, we have sold immunoSEQ as a fee-for-service ~~offering to academic centers and biopharmaceutical customers and further deepened those relationships over time by supporting their development initiatives.~~offering. These research offerings have comprised the ~~vast~~ majority of our revenue to date, although our business is pursuing broader opportunities. As we continue to expand the use of our clonoSEQ diagnostic tests, develop and commercialize ~~immunoSEQ Dx~~T-Detect and develop and commercialize therapeutic product candidates with our drug discovery collaborator, we expect our mix of revenue to shift to clinical products and services, which we believe will become our largest sources of revenue.

We are actively pursuing opportunities to deepen our relationships with current customers and initiate relationships with new customers. We have an experienced, specialty salesforce that is targeting department heads, laboratory directors, principal investigators, core facility directors, clinicians, payors, ~~and~~ research scientists and pathologists at leading academic institutions, biopharmaceutical companies, research institutions and contract research organizations. As MRD assessment becomes standard practice for patient management across a range of blood cancers, we believe it will be essential for clinicians and patients to have access to a highly accurate, sensitive and standardized MRD assessment tool. We are focused on establishing and maintaining collaborative relationships with payors, developing health economic evidence and building billing and patient access infrastructure to expand reimbursement coverage for our clinical diagnostics. We continue to seek expanded coverage of our clonoSEQ diagnostic test and have successfully expanded coverage through contractual agreements or positive medical policies with Medicare and several of the largest national private health insurers in the United States.

We ~~generated~~recognized revenue of ~~$22.1~~$39.5 million and ~~$34.8~~$26.3 million for the three ~~and six~~ months ended ~~June~~September 30, ~~2019,~~2021 and 2020, respectively, and ~~$11.6~~$116.4 million and ~~$21.3~~$68.2 million for the nine months ended September 30, 2021 and 2020, respectively. Net loss attributable to Adaptive Biotechnologies Corporation was $55.9 million and $36.7 million for the three ~~and six~~ months ended ~~June~~September 30, ~~2018, respectively. Our net losses were $15.7~~2021 and 2020, respectively, and $145.8 million and ~~$34.0~~$101.7 million for the ~~three and six~~nine months ended ~~June~~September 30, ~~2019, respectively,~~2021 and ~~$12.5 million and $24.9 million for the three and six months ended June 30, 2018.~~2020, respectively. We have funded our operations to date principally from the sale of convertible preferred stock and common stock and, to a lesser extent, sequencing and development revenue. As of ~~June~~September 30, ~~2019~~2021 and December 31, ~~2018,~~2020, we had cash, cash equivalents and marketable securities of ~~$423.0~~$632.4 million and ~~$165.0~~$806.8 million, respectively. In December 2018, we entered into the Genentech Agreement pursuant to which we received a $300.0 million initial upfront payment in February 2019, may be eligible to receive approximately $1.8 billion over time, including payments upon achievement of specified development, regulatory and commercial milestones, and may receive additional royalties on sales of products commercialized under this agreement.

We derive our revenue from two sources: ~~(i)~~(1) sequencing revenue and ~~(ii)~~(2) development revenue.

Sequencing revenue. Sequencing revenue reflects the amounts generated from providing ~~sequencing services through immunoSEQ to research customers and from providing~~ testing services through clonoSEQ to clinical and research customers, from providing our T-Detect COVID test to clinical customers and from providing sequencing services through immunoSEQ to research customers.

For our clinical customers, we primarily derive revenue from providing our clonoSEQ report to ordering physicians. We bill medical institutions and commercial and government payors based on tests delivered to ordering physicians. Amounts paid for clonoSEQ diagnostic tests by medical institutions and commercial and government payors vary based on respective reimbursement rates and patient responsibilities, which may differ from our targeted list price. To date, the majority of our clonoSEQ diagnostic test revenue has been received from medical institutions. We recognize clinical revenue by evaluating customer payment history, contracted reimbursement rates, if applicable, and other adjustments to estimate the amount of revenue that is collectible.

For our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient’s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test result is delivered and is based upon cumulative tests delivered to date. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and recognized either as we deliver our estimate of the remaining tests in a patient’s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.

For our research customers, which include biopharmaceutical customers and academic institutions, delivery of the sequencing results may include some level of professional support and analysis. Terms with biopharmaceutical customers generally include non-refundable upfront payments, which we record as deferred revenue. For all research customers, we recognize revenue as we deliver sequencing results. From time to time, we offer discounts in order to gain rights and access to certain datasets. Revenue is recognized net of these discounts and costs associated with these services are reflected in cost of revenue.

~~For~~ In periods where our ~~clinical customers,~~sample estimates are reduced or a customer project is cancelled and, in either case, we ~~derive~~have remaining related deferred revenue, ~~from providing our clonoSEQ test report to ordering physicians. We bill commercial payors and medical institutions as~~ we ~~deliver test results to ordering physicians. Amounts paid for clonoSEQ diagnostic tests by commercial payors and medical institutions vary~~recognize revenue using a cumulative catch-up approach based on ~~respective reimbursement rates and patient responsibilities, which may vary from our targeted list price. To date,~~ the ~~majority~~proportion of our clonoSEQ diagnostic test revenue has been received from medical institutions. We recognize clinical revenue by evaluating customer payment history and estimating the amount of revenue that is collectible. As of December 31, 2018, we did not have reimbursement available to us through any government payors for clonoSEQ.

In January 2019, clonoSEQ received Medicare coverage aligned with the FDA label and NCCN guidelines for longitudinal monitoring in MM and ALL. We bill Medicare for an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient’s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue is recognized at the time the initial billable test result is delivered and is based upon cumulative testssamples delivered to ~~date. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and recognized as we deliver~~date relative to the remaining ~~tests in a patient’s treatment cycle.~~samples expected to be delivered.

Development revenue. Development revenue primarily represents regulatory or development support services, other than sequencing revenue, that we provide to biopharmaceutical customers who seek access to our platform to support their therapeutic development activities. ~~Additionally, we generate development revenue from the achievement of regulatory milestones.~~ We enter into collaboration and similar agreements with these customers. When these agreements include sequencing activities, we separately classify those activities as sequencing revenue. These agreements may also include substantial non-refundable upfront payments, which we recognize as development revenue over time as we perform the respective services. Additionally, we generate development revenue from the achievement of regulatory milestones.

During the three months ended September 30, 2021, we executed an intellectual property license agreement that includes variable consideration related to sales-based royalties. Any consideration related to such royalties will be recognized as development revenue at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied (or partially satisfied).

We expect revenue to increase over the long term, particularly as the mix of revenue migrates to clinical diagnostics and drug discovery. The pace by which this mix migrates will be determined by the level of customer adoption and frequency of use of our products and services. ~~However, our~~Our revenue may fluctuate from period to period due to the uncertain nature of delivery of our ~~product~~products and services, the achievement of milestones by us or our customers, timing of expenses incurred, changes in estimates of total anticipated costs related to our Genentech Agreement and ~~milestone achievement.~~other events not within our control, such as the delivery of customer samples or customer decisions to no longer pursue their development initiatives.

Due to the ongoing uncertainties related to the COVID-19 pandemic, we may experience variability in revenue in the near term as our customers’ abilities to procure samples for their research initiatives change, as customer initiatives evolve and as clinical testing is impacted by the pandemic.

Cost of revenue includes the cost of materials, personnel-related expenses (comprised of salaries, benefits and share-based compensation), shipping and handling, equipment and allocated facility costs associated with processing samples and professional support for our sequencing revenue. Allocated facility costs include depreciation of laboratory equipment and allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition. As such, cost of revenue and related volume does not always trend in the same direction as revenue recognition and related volume. Additionally, costs to support our Genentech Agreement are a component of our research and development activities.

We expect cost of revenue to increase in absolute dollars as we grow our sequencing volume and make increased investments in laboratory automation and facilities, but the cost per sample to decrease over the long term due to the efficiencies we may gain as sequencing volume increases from improved utilization of our laboratory capacity, automation and other value engineering initiatives. If our sample volume throughput is reduced as a result of the COVID-19 pandemic or otherwise, cost of revenue as a percentage of total revenue may be adversely impacted due to fixed overhead costs.

Research and development expenses ~~comprise~~consist of laboratory materials costs, personnel-related expenses, equipment costs, allocated facility costs, information technology expenses and contract service expenses. Research and development activities support further development and refinement of existing assays and products, discovery of new technologies and investments ~~into~~in our immune medicine platform. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and ~~workflow, as well as development of applications to support future commercial opportunities.~~workflow. We are currently conducting research and development activities for several products and services and we typically use our laboratory materials, personnel, facilities, information technology and other development resources across multiple development programs. Additionally, certain of these research and development activities benefit more than one of our product opportunities. We do not track research and development expenses by specific product candidates.

A component of our research and development activities is supporting clinical and analytical validations to obtain regulatory approval for future clinical products and services. Additionally, the costs to support our Genentech Agreement are a component of our research and development activities. Some of these activities have generated and may in the future generate development revenue.

We expect our research and development expenses to continue to increase in absolute dollars as we innovate and expand the application of our platform. However, we expect research and development expenses to decrease as a percentage of revenue in the long term, ~~and they~~although the percentage may fluctuate ~~as a percentage of revenue~~ from period to period due to the timing and extent of our ~~efforts needed to develop~~development and ~~commercialize new products and services.~~commercialization efforts.

Sales and marketing expenses consist primarily of personnel-related expenses for commercial sales, account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs, such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility costs.

We expect our sales and marketing expenses to increase in absolute dollars as we expand our commercial sales, marketing and business development teams and increase marketing activities to drive awareness and adoption of our products and services. However, we expect sales and marketing expenses to decrease as a percentage of revenue in the long term, ~~though they may fluctuate as a percentage of revenue~~subject to fluctuations from period to period due to the timing and magnitude of these expenses.

General and administrative expenses consist primarily of personnel-related expenses, including share-based compensation, salaries and benefits for our personnel in executive, legal, finance and accounting, human resources and other administrative functions, including third-party billing services. In addition, these expenses include insurance costs, external legal costs, accounting and tax service expenses, consulting fees and allocated ~~facilities~~facility costs.

We expect our general and administrative expenses to continue to increase in absolute dollars as we increase headcount and incur costs associated with operating as a public company, including expenses related to legal, accounting, regulatory matters, maintaining compliance with exchange listing and requirements of the SEC, director and officer insurance premiums and investor relations.headcount. Though expected to increase in absolute dollars, we expect these expenses to decrease as a percentage of revenue in the long ~~term.~~term as revenue increases.

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018			Three Months Ended September 30,						Nine Months Ended September 30,
	(unaudited)												2021			2020			2021			2020
	(in thousands, except share and per share amounts)												(in thousands, except share and per share amounts)
Statements of Operations Data:
Revenue
Sequencing revenue	$	11,865		$	8,281		$	17,948		$	14,061		$	22,106		$	11,276		$	55,835		$	28,730
Development revenue		10,273			3,287			16,856			7,222			17,361			15,023			60,579			39,467
Total revenue		22,138			11,568			34,804			21,283			39,467			26,299			116,414			68,197
Operating expenses
Cost of revenue		5,734			5,044			10,722			9,033			14,189			6,053			34,945			16,308
Research and development		16,527			9,452			29,010			18,307			36,072			30,314			107,644			80,241
Sales and marketing		8,897			5,329			16,714			10,376			24,949			14,474			68,769			42,813
General and administrative		6,662			4,632			13,666			9,175			20,154			12,079			51,156			36,138
Amortization of intangible assets		423			424			842			843			428			428			1,270			1,275
Total operating expenses		38,243			24,881			70,954			47,734			95,792			63,348			263,784			176,775
Loss from operations		(16,105	)		(13,313	)		(36,150	)		(26,451	)		(56,325	)		(37,049	)		(147,370	)		(108,578	)
Interest and other income, net		446			820			2,105			1,567			327			1,018			1,429			5,805
Income tax (expense) benefit														—			(688	)		—			1,116
Net loss		(15,659	)		(12,493	)		(34,045	)		(24,884	)		(55,998	)		(36,719	)		(145,941	)		(101,657	)
Fair value adjustment to Series E-1 convertible preferred stock options		(710	)		(2	)		(964	)		2
Net loss attributable to common shareholders	$	(16,369	)	$	(12,495	)	$	(35,009	)	$	(24,882	)
Net loss per share attributable to common shareholders, basic and diluted	$	(1.23	)	$	(1.01	)	$	(2.68	)	$	(2.02	)
Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted		13,279,324			12,385,888			13,074,692			12,334,227
Other Fianncial and Operating Data:
Add: Net loss attributable to noncontrolling interest														95			—			95			—
Net loss attributable to Adaptive Biotechnologies Corporation													$	(55,903	)	$	(36,719	)	$	(145,846	)	$	(101,657	)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted													$	(0.40	)	$	(0.27	)	$	(1.04	)	$	(0.79	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted														140,833,564			134,372,026			140,060,379			129,289,948
Other Financial and Operating Data:
Adjusted EBITDA ⁽¹⁾	$	(10,903	)	$	(9,374	)	$	(26,119	)	$	(17,959	)	$	(41,059	)	$	(28,435	)	$	(106,795	)	$	(84,940	)

⁽¹⁾ Adjusted EBITDA is a non-GAAP financial measure that we define as net loss attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, income tax (expense) benefit, ~~(expense),~~ depreciation and amortization and share-based compensation expenses. Please refer to “Adjusted EBITDA” below for a reconciliation between Adjusted EBITDA and net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, and a discussion about the limitations of Adjusted EBITDA.

Total revenue was $22.1 million for the three months ended June 30, 2019 compared to $11.6 million for the three months ended June 30, 2018, representing an increase of approximately $10.6 million, or 91%.

Sequencing revenue increased to $11.9 million for the three months ended June 30, 2019, representing an increase of $3.6 million, or 43%. The increase in sequencing revenue was primarily attributable to an increase of $2.6 million in revenue generated from biopharmaceutical and academic customers and a $1.0 million increase in revenue generated from clinical customers.

The $10.8 million increase in sequencing revenue was primarily attributable to a $5.8 million increase in revenue generated from biopharmaceutical customers and a $5.4 million increase in revenue generated from clinical customers, inclusive of a $1.4 million increase related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote and a change in our estimate of expected cumulative tests per patient for one of our covered indications.

Research sequencing volume increased by ~~22%~~33% to ~~9,084~~8,710 sequences delivered in the three months ended ~~June~~September 30, ~~2019~~2021 from ~~7,457~~6,541 sequences delivered in the three months ended ~~June~~September 30, ~~2018.~~2020. Clinical sequencing volume, excluding T-Detect COVID volume, increased by ~~50%~~47% to ~~2,388~~5,928 clinical tests delivered in the three months ended ~~June~~September 30, ~~2019~~2021 from ~~1,587~~4,023 clinical tests delivered in the three months ended ~~June~~September 30, ~~2018.~~2020.

~~Development~~The $2.3 million increase in development revenue ~~increased to $10.3 million for the three months ended June 30, 2019, representing an increase of $7.0 million, or 213%. The increase~~ was primarily attributable to ~~$8.6~~a $2.7 million ofincrease in revenue generated from the Genentech Agreement, partially offset by a ~~$1.4~~$0.7 million decrease in revenue ~~generated~~recognized from ~~translational~~MRD development agreements, ~~and~~inclusive of a ~~$0.2~~$1.0 million decrease in revenue ~~generated from MRD development agreements.~~

recognized upon the achievement of certain regulatory milestones by our customers’ therapeutics.

~~Cost of revenue was $5.7~~The $8.1 million ~~for the three months ended June 30, 2019, compared to $5.0 million for the three months ended June 30, 2018, representing an increase of $0.7 million, or 14%. The~~ increase in cost of revenue was primarily attributable to ana $3.6 million increase in materials costs resulting from increased revenue sample volume and a $3.0 million increase in labor and overhead costs. Additionally, there was a $0.9 million increase in sample collection costs, a $0.3 million increase in shipping costs and a $0.3 million increase related to higher usage of ~~$0.6~~our production laboratory to process revenue samples versus research and development samples. These increases were partially offset by a $0.3 million decrease in ~~the~~materials cost ~~of overhead and $0.1 million in the cost of materials~~ due to ~~the production laboratory expansion and increased sample volumes.~~product mix.

The following table presents disaggregated research and development expenses by cost classification for the periods presented:

The $5.8 million increase in research and development expenses were $16.5 million for the three months ended June 30, 2019, compared to $9.5 million for the three months ended June 30, 2018, representing an increase of approximately $7.1 million, or approximately 75%. The increase was primarily attributable to ~~$4.0 million in additional cost of materials and allocated production laboratory expenses to support our TCR discovery efforts and other platform expansions,~~ a ~~$2.4~~$4.7 million increase in personnel costs and a ~~$0.5~~$1.6 million increase in depreciation and other expenses, which included a $0.8 million increase in consultant costs.

The $10.5 million increase in sales and marketing expenses was primarily attributable to $6.1 million in additional personnel costs, $3.1 million in additional marketing expenses, a $0.7 million increase in travel and customer event related expenses and a $0.3 million increase in consultant costs. Our clonoSEQ marketing efforts were the largest driver of the $3.1 million increase in marketing expenses.

The $8.1 million increase in general and administrative expenses was primarily attributable to a $3.8 million increase in personnel costs, a $2.6 million increase in building, facility and depreciation related expenses, $0.7 million in additional consultant costs and a $0.6 million increase in computer and software expenses. There was also a $0.2 million increase in insurance costs and a $0.2 million increase in ~~software~~travel and ~~cloud services.~~entertainment expenses. These increases were partially offset by a $0.6 million decrease in legal, accounting and tax fees.

The $0.7 million decrease in interest and other income, net was attributable to a decrease in net interest income and investment amortization resulting from reductions in interest rates and related yields.

The $27.1 million increase in sequencing revenue was primarily attributable to a $17.1 million increase in revenue generated from biopharmaceutical and academic customers, inclusive of a $2.9 million increase due to changes in estimates of total samples to be provided under certain of our MRD development agreements and a $0.7 million decrease in revenue recognized from customer project cancellations. Additionally, there was a $9.9 million increase in revenue generated from clinical customers, inclusive of a $2.0 million increase related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote and a change in our estimate of expected cumulative tests per patient for one of our covered indications.

~~Sales and marketing expenses were $8.9 million for~~Research sequencing volume increased by 35% to 22,636 sequences delivered in the ~~three~~nine months ended ~~June~~September 30, ~~2019, compared to $5.3 million for~~2021 from 16,756 sequences delivered in the ~~three~~nine months ended ~~June~~September 30, ~~2018, representing an increase of $3.6 million, or approximately 67%. The increase was primarily attributable~~2020. Clinical sequencing volume, excluding T-Detect COVID volume, increased by 51% to ~~$2.3 million~~16,160 clinical tests delivered in additional personnel costs, $0.6 million in additional consulting and marketing expenses and $0.5 million in additional travel, entertainment and customer event related expenses. An additional $0.1 million in computer and software expenses also contributed to the ~~overall increase.~~

~~General and administrative expenses were $6.7 million for the three~~nine months ended ~~June~~September 30, ~~2019, compared to $4.6 million for~~2021 from 10,677 clinical tests delivered in the ~~three~~nine months ended ~~June~~September 30, ~~2018, representing an increase of approximately 2.0 million, or approximately 44%.~~ 2020.

The increase was primarily attributable to $1.3 million in additional personnel costs, $0.2 million in additional travel and entertainment related expenses and $0.2 million in additional consulting fees. A $0.1$21.1 million increase in ~~computer and software expenses and a $0.1 million increase in insurance expenses also contributed to the overall increase.~~

Interest and other income was $0.4 million for the three months ended June 30, 2019, compared to $0.8 million for the three months ended June 30, 2018, representing a decrease of $0.4 million, or approximately negative 46%. The decrease was primarily attributable to the $2.2 million impact of revaluing a convertible preferred stock warrant liability in the second quarter of 2019 due to an increase in valuation of our common stock, offset by a $1.9 million increase in interest earned on and investment amortization of a larger portfolio.

Total revenue was $34.8 million for the six months ended June 30, 2019 compared to $21.3 million for the six months ended June 30, 2018, representing an increase of $13.5 million, or approximately 64%.

~~Sequencing revenue increased to $17.9 million for the six months ended June 30, 2019, representing an increase of $3.9 million, or 28%. The increase in sequencing~~development revenue was primarily attributable to an ~~increase of $2.3 million in revenue generated from biopharmaceutical and academic customers, driven by a mix to higher priced products and services, and a $1.6~~$11.9 million increase in revenue generated from ~~clinical customers.~~

Research sequencing volume decreased by 2% to 13,975 sequences delivered in the six months ended June 30, 2019 from 14,315 sequences delivered in the six months ended June 30, 2018. Clinical sequencing volume increased by 44% to 4,399 clinical tests delivered in the six months ended June 30, 2019 from 3,053 clinical tests delivered in the six months ended June 30, 2018.

Development revenue increased to $16.9 million for the six months ended June 30, 2019, representing an increase of $9.6 million, or 133%. The increase was primarily attributable to $14.8 million of revenue generated from the Genentech Agreement ~~offset by a $4.0~~and an $8.3 million ~~decrease~~increase in revenue ~~generated from translational agreements and a $1.2 million decrease in revenue generated~~recognized from MRD development agreements, inclusive of a $7.5 million increase in revenue recognized upon the achievement of certain regulatory milestones by our customers' therapeutics and a $0.3 million increase resulting from a change in estimate of total samples to be provided under certain of our agreements.

~~Cost of revenue was $10.7~~The $18.6 million ~~for the six months ended June 30, 2019, compared to $9.0 million for the six months ended June 30, 2018, representing an increase of $1.7 million, or 19%. The~~ increase in cost of revenue was primarily attributable to an $11.5 million increase ~~of $1.5 million~~ in ~~the cost of~~labor, overhead and ~~$0.1~~facility costs and a $6.5 million ~~in the cost of materials due to the production laboratory expansion and increased sample volumes, as well as an~~ increase in ~~personnel~~materials costs ~~of $0.1 million. This~~resulting from increased revenue sample volume. Additionally, there was a $1.2 million increase ~~was~~in sample collection costs and a $0.9 million increase in shipping costs. These increases were partially offset by a ~~$0.1~~$2.0 million decrease ~~in computer~~related to higher usage of our production laboratory to process research and ~~software expenses.~~development samples versus revenue samples.

The following table presents disaggregated research and development expenses by cost classification for the periods presented:

~~Research~~The $27.4 million increase in research and development expenses ~~were $29.0 million for the six months ended June 30, 2019, compared to $18.3 million for the six months ended June 30, 2018, representing an increase of $10.7 million, or 58%. The increase~~ was primarily attributable to ~~$5.5~~a $13.8 million increase in ~~additional~~personnel costs, a $6.5 million increase in depreciation and other expenses, which included a $2.3 million increase in collaboration and medical advisory costs and a $1.6 million increase in consultant costs, and a $6.1 million increase in cost of materials and allocated production laboratory expenses. The increase in cost of materials and allocated production laboratory expenses ~~to support~~was primarily driven by increased investments in our ~~TCR~~drug discovery efforts and ~~other platform expansions, $4.0 million increase in personnel costs, a $0.8 million increase in depreciation~~T-Detect and ~~other expenses, a $0.3 million increase in software and cloud service costs and an increase in allocable facilities and information technology costs of $0.2 million.~~TCR-Antigen Map development.

~~Sales~~The $26.0 million increase in sales and marketing expenses ~~were $16.7 million for the six months ended June 30, 2019, compared to $10.4 million for the six months ended June 30, 2018, representing an increase of $6.3 million, or 61%. The increase~~ was primarily attributable to ~~$3.9~~$18.1 million in additional personnel costs, ~~$1.2~~$5.5 million in additional ~~travel, entertainment~~marketing expenses, a $1.2 million increase in consultant costs and ~~customer event related expenses~~a $0.5 million increase in computer and ~~$1.0~~software expenses. Our clonoSEQ and T-Detect marketing efforts were the largest drivers of the $5.5 million increase in marketing expenses.

~~additional consulting~~General and ~~marketing expenses. An additional $0.2 million in computer and software expenses also contributed to the overall increase.~~Administrative

~~General~~The $15.0 million increase in general and administrative expenses ~~were $13.7 million for the six months ended June 30, 2019, compared to $9.2 million for the six months ended June 30, 2018, representing an increase of $4.5 million, or 49%. The increase~~ was primarily attributable to ~~$1.7 million in additional personnel costs, $1.2 million in additional business taxes, largely due to the Genentech upfront payment received in February 2019, and~~ a ~~$0.9~~$9.9 million increase in ~~legal, tax, accounting~~personnel costs, as well as a $3.6 million increase in building, facility and ~~consultant fees. A $0.2~~depreciation related expenses. Additionally, there was a $1.5 million increase in computer and software expenses, a ~~$0.2~~$1.2 million increase in ~~travel~~consultant costs and ~~entertaining expenses,~~ a ~~$0.1~~$0.7 million increase in insurance ~~expense~~costs. These increases were partially offset by a $1.8 million decrease in legal, accounting and ~~a $0.1 million increase in administration costs also contributed to the overall increase.~~tax fees.

~~Interest~~The $4.4 million decrease in interest and other income, ~~was $2.1 million for the six months ended June 30, 2019, compared to $1.6 million for the six months ended June 30, 2018, representing an increase of $0.5 million, or approximately 34%. The increase~~net was primarily attributable to a ~~$2.8~~$4.2 million ~~increase~~decrease in net interest ~~earned on~~income and investment amortization ~~of a larger portfolio, offset by the $2.3 million impact of revaluing a convertible preferred stock warrant liability~~resulting from reductions in ~~2019.~~interest rates and related yields.

Adjusted EBITDA is a non-GAAP financial measure that we define as net loss attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, income tax (expense) benefit, ~~(expense),~~ depreciation and amortization and share-based compensation expenses.

Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.

Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA does not reflect:

In addition, Adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries.

The following is a reconciliation of ~~our~~ net loss attributable to Adaptive Biotechnologies Corporation to Adjusted EBITDA for the periods presented (in thousands):

⁽¹⁾ Represents share-based compensation expense related to option and restricted stock unit awards. See Note 11 of the accompanying notes to our unaudited condensed consolidated financial statements ~~appearing~~included elsewhere in this report for details on our share-based compensation expense.

We have incurred losses since inception and have incurred negative cash flows from operations ~~from~~since inception through ~~December 31, 2018.~~September 30, 2021, with the exception of certain 2019 periods for which we had positive cash flows from operations. As of ~~June~~September 30, ~~2019,~~2021, we had an accumulated deficit of ~~$330.9~~$657.5 million.

We have funded our operations to date principally from the sale of convertible preferred stock and common stock and, to a lesser extent, sequencing and development revenue. In December 2018, we entered into the Genentech Agreement pursuant to which we received a $300.0 million initial upfront payment in February 2019, may receive approximately $1.8 billion over time, including payments upon achievement of specified development, regulatory and commercial milestones, and may receive additional royalties on sales of products commercialized under this agreement. As of ~~June~~September 30, ~~2019,~~2021, we had cash, cash equivalents and marketable securities of ~~$423.0~~$632.4 million.

We believe ~~our cash flows from operations and~~ our existing cash, cash equivalents and marketable securities ~~together with the net proceeds from our IPO that closed July 1, 2019,~~ will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months. We may consider raising additional capital to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons.

We plan to utilize the existing cash, cash equivalents and marketable securities on hand primarily to fund our commercial and marketing activities associated with our clinical products and services, continued research and development initiatives for our pipeline candidates and drug discovery initiatives, ongoing investments into our immune medicine platform and scaling of our laboratory operations with our anticipated growth. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our funds are held in money market funds and marketable securities consisting of U.S. government debt securities, U.S. government agency bonds, commercial paper and corporate bonds.

As revenue from sales of immunoSEQ and clonoSEQ is expected to grow, we expect our accounts receivable and inventory balances to increase. Any increase in accounts receivable and inventory may not be completely offset by increases in accounts payable and accrued expenses, which could result in greater working capital requirements. Moreover, following the closing of our IPO, we expect to incur additional costs associated with operating as a public company, including expenses related to legal, accounting, regulatory, exchange listing and SEC compliance matters.

If our available cash, cash equivalents and marketable securities balances ~~net proceeds from our IPO that closed July 1, 2019~~ and anticipated cash ~~flow~~flows from operations are insufficient to satisfy our liquidity requirements, we may seek to sell additional equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. The sale of equity and convertible debt securities may result in dilution to our shareholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. ~~Additional~~This additional capital may not be available on reasonable terms, or at all.

We plan to utilize the existing cash, cash equivalents and marketable securities on hand primarily to fund our commercial and marketing activities associated with our clinical products and services, continued research and development initiatives for our pipeline candidates and drug discovery initiatives and ongoing investments in our immune medicine platform. We also expect to make increased capital expenditures in the near term related to the expansion of our office and laboratory space and expect to increase investment in laboratory equipment and operations to support our anticipated growth. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to capital preservation and liquidity. Currently, our funds are held in money market funds and marketable securities consisting of U.S. government debt securities and corporate bonds.

There have been no material changes outside the ordinary course of business to our contractual obligations and commitments as previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020. See Note 8 of the accompanying notes to our unaudited condensed consolidated financial statements included elsewhere in this report for more information regarding our contractual obligations relating to lease agreements.

While we may experience variability in revenue in the near term, as long-term revenue from sales of our current and future products and services is expected to grow, we expect our accounts receivable and inventory balances to increase. Any increase in accounts receivable and inventory may not be completely offset by increases in accounts payable and accrued expenses, which could result in greater working capital requirements.

The following table summarizes our uses and sources of cash for the ~~periods presented~~nine months ended September 30, 2021 and 2020 (in thousands):

Cash ~~provided by~~used in operating activities during the ~~six~~nine months ended ~~June~~September 30, ~~2019~~2021 was ~~$262.3~~$138.9 million, which was primarily attributable to a net loss of $145.9 million and a net change in operating assets and liabilities of $44.6 million, partially offset by noncash share-based compensation of $31.4 million, noncash depreciation and amortization of $15.1 million and noncash lease expense of $5.3 million. The net change in operating assets and liabilities was primarily due to a $46.3 million reduction in deferred revenue primarily related to revenue recognized from the Genentech Agreement, an increase in accounts receivable, net of $7.1 million, an increase in inventory of $4.2 million and increases in prepaid expenses and other current assets of $2.2 million, all of which were partially offset by an increase in operating lease liabilities of $9.9 million and increases in accounts payable and accrued liabilities of $5.5 million.

Cash used in operating activities during the nine months ended September 30, 2020 was $109.8 million, which was primarily attributable to a net loss of $101.7 million, a net change in our operating assets and liabilities of ~~$286.1~~$32.5 million ~~non-cash~~and a benefit from income tax of $1.1 million, which were partially offset by noncash share-based compensation of ~~$6.4~~$17.5 million, ~~non-cash~~noncash depreciation and amortization of ~~$1.8~~$5.6 million and ~~a $2.3 million fair value adjustment~~noncash lease expense of ~~the convertible preferred stock warrant liability due to an increase in valuation of our common stock, partially offset by a net loss of $34.0~~$2.2 million. The net change in our operating assets and liabilities was primarily ~~reflects an increase~~due to a $27.3 million reduction in deferred revenue ~~of $288.7~~primarily related to revenue recognized from the Genentech Agreement, a $3.9 million primarily due to the $300.0 million upfront payment by Genentech, and an increase in accounts payable and accrued liabilities of $1.3 million primarily due to growth in operating expenses and timing of vendor payments, partially offset by an increase in accounts receivable of $2.4 million primarily due to an increase in sequencing revenue paid in arrears rather than upfront by biopharmaceutical customers, an increase in prepaid expenses and other current assets ~~of $0.9 million primarily due to receivables from investment maturities~~ and a ~~$0.5~~$1.7 million ~~decrease~~increase in ~~deferred rent due to increased cash rent payments.~~inventory. These changes were partially offset by a reduction in accounts receivable, net of $0.8 million.

Cash ~~used in operating~~provided by investing activities during the ~~six~~nine months ended ~~June~~September 30, ~~2018~~2021 was ~~$15.2~~$114.0 million, which was primarily attributable to ~~a net loss~~proceeds from maturities of ~~$24.9~~marketable securities of $404.5 million, partially offset by non-cash share-based compensation of $5.6 million, non-cash depreciation and amortization of $2.5 million and a net change in our operating assets and liabilities of $1.7 million. The net change in our operating assets and liabilities reflects a $5.4 million increase in deferred revenue primarily due to upfront payments from MRD biopharmaceutical agreements, a decrease in accounts receivable of $1.2 million primarily due to the timing of receipts, partially offset by an increase in inventory of $2.9 million to support growth in revenue and research and development activities, a decrease in accounts payable and accrued liabilities of $1.0 million primarily due to corporate bonus payments and reduction in marketing and legal payables, an increase in prepaid expenses and other current assets of $0.4 million primarily due to receivables from investment maturities and reductions in deferred rent of $0.4 million due to increased cash rent payments.

~~Cash used in investing activities during the six months ended June 30, 2019 was $267.5 million, which was primarily attributable to~~ purchases of marketable securities of ~~$358.7~~$238.0 million and purchases of property and equipment of ~~$5.4 million, partially offset~~$52.5 million.

~~Cash used in~~ investing activities during the ~~six~~nine months ended ~~June~~September 30, ~~2018~~2020 was ~~$32.0~~$223.0 million, which was primarily attributable to proceeds from sales and maturities of marketable securities of $532.2 million, partially offset by purchases of marketable securities of ~~$110.9~~$299.8 million and purchases of property and equipment of ~~$1.6 million, partially offset by maturities of marketable securities of $80.5~~$9.4 million.

Cash used by financing activities during the six months ended June 30, 2019 was $1.4 million, which was primarily attributable to payment of deferred IPO costs of $3.4 million, partially offset by proceeds of $2.0 million from the exercise of stock options.

Cash provided by financing activities during the ~~six~~nine months ended ~~June~~September 30, ~~2018~~2021 was ~~$0.9~~$23.9 million, which was primarily attributable to proceeds from the exercise of stock options.

Cash provided by financing activities during the nine months ended September 30, 2020 was $287.3 million, which was primarily attributable to $271.8 million in proceeds, after deducting underwriting discounts and net offering expenses payable by us, received from our underwritten public offering completed in July 2020, as well as $15.5 million in proceeds from the exercise of stock options.

Our principal contractual obligations and commitments were reported in our Prospectus. As of June 30, 2019, there have been no material changes to our contractual obligations and commitments as disclosed in our Prospectus.

Utilization of our ~~NOL~~net operating loss (“NOL”) carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986 (“Section 382”) and similar state provisions. The annual limitation may result in the expiration of NOL carryforwards and credits before utilization. If there should be an ownership change, our ability to utilize our NOL carryforwards and credits could be limited. We have completed a Section 382 analysis ~~and~~for changes in ownership through December 31, 2020. Based on this analysis, we do not expect to have ~~determined there are no~~any permanent limitations on the utilization of ~~approximately $186.9 million of~~ our federal ~~NOLs as~~NOLs. Under the Tax Cuts and Jobs Act of ~~December 31, 2018.~~2017, federal net operating losses incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOL is subject to an annual limitation. Net operating losses generated prior to 2018 are eligible to be carried forward up to 20 years. Based on the available objective evidence, management determined that it was more likely than not that the net deferred tax assets would not be realizable as of December 31, ~~2018.~~2020. Accordingly, management applied a full valuation allowance against net deferred tax assets as of December 31, ~~2018.~~

~~As of June 30, 2019~~2020. In March 2020, under the newly enacted Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), NOLs arising in tax years beginning after December 31, ~~2018, we have not had any off-balance sheet arrangements, as defined in the rules~~2017 and ~~regulations~~before January 1, 2021 may be carried back to each of the ~~SEC.~~five tax years preceding the tax year of the loss. Additionally, the CARES Act temporarily removes the 80% limitation, reinstating it for tax years beginning after 2020. However, none of these provisions have an impact on our tax provision.

We have prepared our financial statements in accordance with GAAP. Our preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities and related disclosures at the date of the financial statements, as well as revenue and expense recorded during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and or other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas, including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, ~~including the fair value of common stock granted prior to our IPO,~~ the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.

While our significant accounting policies are described in more detail in our ~~Prospectus,~~Annual Report on Form 10-K for the year ended December 31, 2020, as well as in Note 2 of the accompanying notes to our unaudited condensed consolidated financial statements included elsewhere in this report, we believe the following accounting policies are critical to the judgments and estimates used in the preparation of our financial statements:

There have been no material changes to our critical accounting policies and estimates as previously disclosed in our ~~Prospectus.~~

~~We are an “emerging growth company” within~~Annual Report on Form 10-K for the meaning of the JOBS Act. The JOBS Act allows an emerging growth company to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. We have elected to use this extended transition period and, as a result, our financial statements may not be comparable to companies that comply with public company effective dates. We also intend to rely on other exemptions provided by the JOBS Act, including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act.

~~We will remain an emerging growth company until the earliest of (1) the last day of the fiscal~~ year following the fifth anniversary of the closing of the IPO, (2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (3) the last day of the fiscal year in which we are deemed to be a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act of 1934, as amended (“Exchange Act”), which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year or (4) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.ended December 31, 2020.

~~See Note 2 to the unaudited condensed financial statements included elsewhere in this report for more information.~~

We are exposed to market risk for changes in interest rates related primarily to our cash, ~~and~~ cash equivalents and marketable securities. As of ~~June~~September 30, ~~2019, we had cash~~2021, there have been no material changes to our market risks as previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020. We do not enter into investments for trading purposes and cash equivalents of $48.5 million, held primarily in cash deposits, money market funds, commercial paper and U.S. government debt securities. Our marketable securities are held in U.S. government debt securities, U.S. government agency bonds, commercial paper and corporate bonds. As of June 30, 2019, we had short-term marketable securities of $374.5 million. Our primary exposurehave not used any derivative financial instruments to ~~market~~manage our interest rate risk is interest income sensitivity, which is affected by changes in the general level of interest rates in the United States. As of June 30, 2019, a hypothetical 100 basis point increase in interest rates would have resulted in an approximate $1.4 million decline of the fair value of our available-for-sale securities. This estimate is based on a sensitivity model that measures market value changes when changes in interest rates occur.exposure.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of ~~June~~September 30, ~~2019.~~2021. There was not any change in our internal control over financial reporting (as such term is defined in ~~Rules~~Rule 13a-15(f) under the Exchange Act) during the ~~quarter~~three months ended ~~June~~September 30, ~~2019~~2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Investing in our common stock involves a high degree of risk. ~~Our risk factors~~We operate in a rapidly changing environment that involves a number of risks that could materially affect our business, financial condition or future results, some of which are beyond our control. In addition to the other information set forth in ~~our Prospectus and incorporated herein by reference, and there have been no material changes to such risk factors. You should carefully consider~~this report, the risks and uncertainties that we ~~describe~~believe are most important for you to consider are discussed in Part I, Item 1A under the ~~Prospectus, together with all~~caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020. The risk factors may be important to understanding other ~~information~~statements in this report ~~including our~~and should be read in conjunction with the unaudited condensed consolidated financial statements and related notes ~~and the “Management’s Discussion and Analysis~~in this report. The occurrence of ~~Financial Condition~~any single risk or any combination of risks could materially and ~~Results of Operations” section of this report, before investing in our common stock. Any of the risk factors we describe in the Prospectus could~~ adversely affect our business, operations, product pipeline, operating results, financial condition ~~results of operations~~ or ~~prospects. The market price~~liquidity, and consequently, the value of our ~~common stock could decline if one or more of these risks or uncertainties actually occur, causing you to lose all or part of your investment in our common stock. Additional~~securities. Further, additional risks that we currently do not know about or that we currently believe to be immaterial may also impair our business, financial condition, operating results and prospects.

There have been no material changes to the risk factors described in the Annual Report on Form 10-K for the year ended December 31, 2020.

~~During the quarter ended June 30, 2019, we had the following unregistered securities transactions:~~

The issuances of the securities described above were exempt from registration pursuant to Section 4(a)(2) of the Securities Act as transactions by an issuer not involving a public offering or Rule 701 promulgated under the Securities Act as transactions pursuant to compensatory benefit plans. The shares of common stock issued upon the exercise of options are deemed to be restricted securities for purposes of the Securities Act.

On July 1, 2019, we closed our IPO, in which we issued and sold 17,250,000 shares of our common stock (including the full exercise of the underwriters’ overallotment option) at a public offering price of $20.00 per share for an aggregate offering price of $345.0 million. Net proceeds to us were $316.0 million after deducting aggregate underwriting discounts and commissions of $24.2 million and estimated offering expenses of $4.8 million. Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and BofA Securities, Inc. acted as joint lead book-running managers for the offering. Cowen and Company, LLC and Guggenheim Securities, LLC acted as book-running managers for the offering. William Blair & Company, L.L.C. and BTIG, LLC acted as co-managers for the offering. All of the shares of common stock issued and sold in the offering were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-231838), which was declared effective by the SEC on June 26, 2019. Following the sale of these shares, the offering terminated. No payments were made by us to directors, officers or persons owning 10% or more of any class of our equity securities or to any of our affiliates. There has been no material change in the planned use of proceeds from our IPO as described in our Prospectus. As our IPO closed after the period covered by this report, none of the proceeds from our IPO were used during the period covered by this report.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Washington	27-0907024
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
~~1551~~1165 Eastlake Avenue East ~~Suite 200~~ Seattle, Washington	~~98102~~98109
(Address of principal executive offices)	(Zip Code)

		Page
PART I.	FINANCIAL INFORMATION	4
Item 1.	Financial Statements (Unaudited)	4
	Condensed Consolidated Balance Sheets	4
	Condensed Consolidated Statements of Operations	5
	Condensed Consolidated Statements of Comprehensive Loss	6
	Condensed Consolidated Statements of ~~Convertible Preferred Stockand~~Shareholders’~~Deficit~~ Equity	7
	Condensed Consolidated Statements of Cash Flows	9
	Notes to Unaudited Condensed Consolidated Financial Statements	10
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2524
Item 3.	Quantitative and Qualitative Disclosures ~~about~~About Market Risk	3634
Item 4.	Controls and Procedures	3634
PART II.	OTHER INFORMATION	3735
Item 1.	Legal Proceedings	3735
Item 1A.	Risk Factors	3735
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3735
Item 3.	Defaults Upon Senior Securities	3735
Item 4.	Mine Safety Disclosures	3835
Item 5.	Other Information	3835
Item 6.	Exhibits	3836
Signatures		3937

	Less Than 12 Months					12 Months Or Greater
	Fair Value		Unrealized Loss			Fair Value		Unrealized Loss
U.S. government debt securities	$	163,664	$	(74	)	$	—	$	—
Corporate bonds		22,888		(13	)		—		—
Total available-for-sale securities	$	186,552	$	(87	)	$	—	$	—

	June 30, 2019
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		September 30, 2021
	(unaudited)							Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Acquired developed technology	$	20,000	$	(7,462	)	$	12,538	$	20,000	$	(11,217	)	$	8,783
Purchased intellectual property		325		(79	)		246		325		(153	)		172
Balance at June 30, 2019	$	20,325	$	(7,541	)	$	12,784
Balance at September 30, 2021								$	20,325	$	(11,370	)	$	8,955

	December 31, 2018							December 31, 2020
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Acquired developed technology	$	20,000	$	(6,636	)	$	13,364	$	20,000	$	(9,972	)	$	10,028
Purchased intellectual property		325		(63	)		262		325		(128	)		197
Balance at December 31, 2018	$	20,325	$	(6,699	)	$	13,626
Balance at December 31, 2020								$	20,325	$	(10,100	)	$	10,225

	Convertible preferred stock					Common stock				Additional paid-in			Accumulated other comprehensive			Accumulated			Total shareholders’
	Shares		Amount			Shares		Amount		capital			(loss) income			deficit			deficit
Balance as of March 31, 2018 (unaudited)		92,745,734	$	561,396			12,301,844	$	1	$	28,620		$	(283	)	$	(261,950	)	$	(233,612	)
Issuance of common stock for cash upon exercise of stock options (unaudited)		—		—			245,000		—		415			—			—			415
Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value (unaudited)		44,360		35			—		—		—			—			—			—
Vested Series E-1 convertible preferred stock option forfeitures (unaudited)		—		(767	)		—		—		476			—			291			767
Series E-1 convertible preferred stock option share-based compensation (unaudited)		—		—			—		—		1			—			—			1
Adjustment to redemption value for vested Series E-1 convertible preferred stock options (unaudited)		—		1			—		—		(1	)		—			—			(1	)
Change in redemption value for vested Series E-1 convertible preferred stock options (unaudited)		—		2			—		—		—			—			(2	)		(2	)
Common stock option share-based compensation (unaudited)		—		—			—		—		2,447			—			—			2,447
Other comprehensive income (unaudited)		—		—			—		—		—			43			—			43
Net loss (unaudited)		—		—			—		—		—			—			(12,493	)		(12,493	)
Balance as of June 30, 2018 (unaudited)		92,790,094	$	560,667			12,546,844	$	1	$	31,958		$	(240	)	$	(274,154	)	$	(242,435	)

Balance as of March 31, 2019 (unaudited)		93,023,694	$	561,210			12,930,536	$	1	$	40,981		$	92		$	(314,548	)	$	(273,474	)
Issuance of common stock for cash upon exercise of stock options (unaudited)		—		—			794,845		—		1,847			—			—			1,847
Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value (unaudited)		16,043		11			—		—		—			—			—			—
Change in redemption value for vested Series E-1 convertible preferred stock options (unaudited)		—		710			—		—		—			—			(710	)		(710	)
Common stock option share-based compensation (unaudited)		—		—			—		—		3,332			—			—			3,332
Other comprehensive income (unaudited)		—		—			—		—		—			290			—			290
Net loss (unaudited)		—		—			—		—		—			—			(15,659	)		(15,659	)
Balance as of June 30, 2019 (unaudited)		93,039,737	$	561,931			13,725,381	$	1	$	46,160		$	382		$	(330,917	)	$	(284,374	)

Balance as of December 31, 2017	92,656,029	$	561,333		12,208,731	$	1	$	24,972		$	(166	)	$	(249,423	)	$	(224,616	)
Adjustments to accumulated deficit for adoption of guidance on accounting for share-based payment transactions (unaudited)	—		—		—		—		140			—			(140	)		—
Issuance of common stock for cash upon exercise of stock options (unaudited)	—		—		338,113		—		823			—			—			823
Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value (unaudited)	134,065		100		—		—		—			—			—			—
Vested Series E-1 convertible preferred stock option forfeitures (unaudited)	—		(767	)	—		—		476			—			291			767
Series E-1 convertible preferred stock option share-based compensation (unaudited)	—		—		—		—		3			—			—			3
Adjustment to redemption value for vested Series E-1 convertible preferred stock options (unaudited)	—		3		—		—		(3	)		—			—			(3	)
Change in redemption value for vested Series E-1 convertible preferred stock options (unaudited)	—		(2	)	—		—		—			—			2			2
Common stock option share-based compensation (unaudited)	—		—		—		—		5,547			—			—			5,547
Other comprehensive loss (unaudited)	—		—		—		—		—			(74	)		—			(74	)
Net loss (unaudited)	—		—		—		—		—			—			(24,884	)		(24,884	)
Balance as of June 30, 2018 (unaudited)	92,790,094	$	560,667		12,546,844	$	1	$	31,958		$	(240	)	$	(274,154	)	$	(242,435	)

Balance as of December 31, 2018	92,790,094	$	560,858		12,841,536	$	1	$	37,902		$	(107	)	$	(295,908	)	$	(258,112	)
Issuance of common stock for cash upon exercise of stock options (unaudited)	—		—		883,845		—		1,880			—			—			1,880
Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value (unaudited)	249,643		109		—		—		—			—			—			—
Change in redemption value for vested Series E-1 convertible preferred stock options (unaudited)	—		964		—		—		—			—			(964	)		(964	)
Common stock option share-based compensation (unaudited)	—		—		—		—		6,378			—			—			6,378
Other comprehensive income (unaudited)	—		—		—		—		—			489			—			489
Net loss (unaudited)	—		—		—		—		—			—			(34,045	)		(34,045	)
Balance as of June 30, 2019 (unaudited)	93,039,737	$	561,931		13,725,381	$	1	$	46,160		$	382		$	(330,917	)	$	(284,374	)

	June 30, 2019			December 31, 2018
	(unaudited)
Fair value estimate	$	48.30		$	8.27
Expected term (in years)		1.81			2.31
Risk-free interest rate		1.8	%		2.5	%
Expected volatility		61.1	%		55.3	%
Expected dividend yield		—			—

	June 30, 2019
	Amortized Cost		Unrealized Gain		Unrealized Loss			Estimated Fair Value		September 30, 2021
	(unaudited)									Amortized Cost		Unrealized Gain		Unrealized Loss			Estimated Fair Value
Short-term marketable securities
Commercial paper	$	82,165	$	—	$	—		$	82,165
U.S. government debt and agency securities		269,366		351		(1	)		269,716
U.S. government debt securities										$	277,331	$	87	$	—		$	277,418
Corporate bonds		22,630		32		—			22,662		15,225		1		(5	)		15,221
Total short-term marketable securities	$	374,161	$	383	$	(1	)	$	374,543	$	292,556	$	88	$	(5	)	$	292,639
Long-term marketable securities
U.S. government debt securities										$	204,694	$	6	$	(74	)	$	204,626
Corporate bonds											12,761		—		(8	)		12,753
Total long-term marketable securities										$	217,455	$	6	$	(82	)	$	217,379

	Less Than 12 Months				12 Months Or Greater
	Fair Value		Unrealized Loss		Fair Value		Unrealized Loss
	(unaudited)
Short-term marketable securities
U.S. government debt and agency securities	$	—	$	—	$	4,997	$	(1	)
Total short-term marketable securities	$	—	$	—	$	4,997	$	(1	)

2019	$	856
2020		1,698
2021		1,698
2021 (excluding the nine months ended September 30, 2021)			$	429
2022		1,698		1,699
2023		1,698		1,699
2024				1,703
2025				1,699
Thereafter		5,136		1,726
Total future amortization expense	$	12,784	$	8,955

Deferred revenue balance at December 31, 2018	$	13,399
Additions to deferred revenue during the period (unaudited)		308,055
Revenue recognized during the period (unaudited)		(19,341	)
Deferred revenue balance at June 30, 2019 (unaudited)	$	302,113

Deferred revenue balance at December 31, 2020	$	236,937
Additions to deferred revenue during the period		26,720
Revenue recognized during the period		(73,065	)
Deferred revenue balance at September 30, 2021	$	190,592

2019	$	1,781
2020		3,819
2021		3,917
2022		4,017
2023		2,295
Thereafter		2,315
Total future minimum lease payments	$	18,144

Weighted-average remaining lease term (in years)			10.75
Weighted-average discount rate			4.6	%

2021 (excluding the nine months ended September 30, 2021)	$	2,757
2022		14,184
2023		13,964
2024		13,692
2025		14,098
Thereafter		93,518
Total undiscounted lease payments		152,213
Less:
Imputed interest rate		(33,755	)
Tenant improvement receivables		(5,306	)
Total operating lease liabilities	$	113,152
Less: current portion		(5,108	)
Operating lease liabilities, less current portion	$	108,044

	Shares Authorized		Shares Issued and Outstanding		Amount			Liquidation Preference
Series A		4,550,000		4,550,000	$	12,405		$	4,550
Series B		5,645,706		5,645,706		16,018			9,669
Series C		4,804,227		4,747,352		14,425			12,521
Series D		19,269,117		19,269,117		106,905			106,999
Series E		15,524,350		15,524,350		93,698			93,750
Series E-1		17,407,441		16,854,887		73,640	⁽¹⁾		101,785
Series F		21,761,676		21,761,676		195,013			195,100
Series F-1		4,800,000		4,686,649		49,827			50,000
Total convertible preferred stock		93,762,517		93,039,737	$	561,931		$	574,374

Shares ~~to be issued~~issuable upon ~~conversion~~the exercise of ~~all series~~outstanding common stock options and the vesting of ~~convertible preferred~~outstanding common restricted stock units granted			~~93,039,737~~
~~Shares to be issued upon exercise of outstanding common stock options~~			~~17,681,436~~13,645,411
Shares available for future ~~stock option grants~~grant under the 2019 Equity Incentive Plan			~~3,155,968~~23,011,065
Shares ~~to be issued upon exercise of outstanding Series E-1 convertible preferred stock options~~available for future grant under the Employee Stock Purchase Plan			~~15,034~~2,804,298
~~Shares to be issued upon conversion of Series C convertible preferred stock in connection with warrant exercise~~			~~56,875~~
~~Shares to be issued upon conversion of common stock warrants~~			~~55,032~~
~~Shares~~Total shares of common stock reserved for future issuance			~~114,004,082~~39,460,774

	Shares Available for Grant			Shares Subject to Outstanding Options			Weighted- Average Exercise Price per Share		Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2018		6,827,996			14,893,253		$	4.59	$	39,864
Options granted (unaudited)		(3,890,331	)		3,890,331			7.55
Forfeited or cancelled (unaudited)		218,303			(218,303	)		6.19
Exercised (unaudited)		—			(883,845	)		2.13
Outstanding at June 30, 2019 (unaudited)		3,155,968			17,681,436			5.35		759,479

	Shares Available for Grant
Shares available for grant at December 31, 2020		18,617,001
2019 Equity Incentive Plan reserve increase effective January 1, 2021		6,882,344
Options and restricted stock units granted		(3,295,903	)
Options and restricted stock units forfeited, cancelled or expired		807,623
Shares available for grant at September 30, 2021		23,011,065

	Shares Subject to Outstanding Options			Weighted-Average Exercise Price per Share		Aggregate Intrinsic Value (in thousands)
Options outstanding at December 31, 2020		14,433,560		$	12.82	$	668,458
Options granted		2,407,629			41.21
Options forfeited or cancelled		(744,501	)		24.48
Options expired		(21,452	)		18.98
Options exercised		(3,310,804	)		7.04
Options outstanding at September 30, 2021		12,764,432		$	18.98	$	218,168
Options vested and exercisable at September 30, 2021		7,080,906		$	10.29	$	170,535

	Restricted Stock Units Outstanding			Weighted-Average Grant Date Fair Value per Share
Nonvested outstanding restricted stock units at December 31, 2020		50,000		$	28.10
Restricted stock units granted		888,274			40.21
Restricted stock units forfeited or cancelled		(41,670	)		45.06
Restricted stock units vested		(15,625	)		28.10
Nonvested outstanding restricted stock units at September 30, 2021		880,979		$	39.51

	Convertible Preferred Shares Subject to Outstanding Options			Weighted- Average Exercise Price per Share		Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2018		264,677		$	0.44	$	1,826
Options granted (unaudited)		—			—
Forfeited or cancelled (unaudited)		—			—
Exercised (unaudited)		(249,643	)		0.44
Outstanding at June 30, 2019 (unaudited)		15,034			0.49		719

	Adaptive 2009 Equity Incentive Plan
	Six Months Ended June 30,
	2019			2018
	(unaudited)
Grant date fair value	$	8.55		$	6.55
Expected term (in years)		6.06			6.16
Risk-free interest rate		2.4	%		2.7	%
Expected volatility		67.9	%		69.2	%
Expected dividend yield		—			—

2019	$	1,431
2020		3,053
2021		5,802
2022		9,706
2023		9,975
Thereafter		105,270
Total future minimum lease payments	$	135,237

	Three Months Ended June 30,				Change					Percent of Revenue
(in thousands, except percentages)	2019		2018		$		%			2019			2018
	(unaudited)
Revenue
Sequencing revenue	$	11,865	$	8,281	$	3,584		43	%		54	%		72	%
Development revenue		10,273		3,287		6,986		213			46			28
Total revenue	$	22,138	$	11,568	$	10,570		91	%		100	%		100	%

	Three Months Ended June 30,							Three Months Ended September 30,
(in thousands)	2019		2018		Change			2021		2020		Change
	(unaudited)
Research and development materials and allocated production laboratory expenses	$	7,589	$	3,605	$	3,984		$	12,620	$	13,095	$	(475	)
Personnel expenses		6,765		4,344		2,421			16,184		11,447		4,737
Allocable facilities and information technology expenses		783		815		(32	)		1,560		1,468		92
Software and cloud services expenses		462		244		218			825		976		(151	)
Depreciation and other expenses		928		444		484			4,883		3,328		1,555
Total	$	16,527	$	9,452	$	7,075		$	36,072	$	30,314	$	5,758

	Six Months Ended June 30,				Change					Percent of Revenue
(in thousands, except percentages)	2019		2018		$		%			2019			2018
	(unaudited)
Revenue
Sequencing revenue	$	17,948	$	14,061	$	3,887		28	%		52	%		66	%
Development revenue		16,856		7,222		9,634		133			48			34
Total revenue	$	34,804	$	21,283	$	13,521		64	%		100	%		100	%


		Incorporated by Reference
Exhibit Number	Exhibit Title	Form	File No.	Exhibit	Filing Date	Filed Herewith
3.1	Amended and Restated Articles of Incorporation	8-K	001-38957	3.1	7/1/2019
3.2	Amended and Restated Bylaws	8-K	001-38957	3.2	7/1/2019
4.1	Seventh Amended and Restated Investors’ Rights Agreement among the Registrant and certain of its shareholders, dated May 30, 2019	S-1	333-231838	4.1	5/30/2019
10.1†	Master Terms & Conditions of Sale between Illumina, Inc. and the Registrant, dated May 28, 2019	S-1/A	333-231838	10.3	6/17/2019
10.2	Amended and Restated Side Letter Agreement among Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Long Fund Master Ltd. and the Registrant, dated May 8, 2019	S-1	333-231838	10.5	5/30/2019
10.3	Form of Amended and Restated Employment Agreement between the Registrant and certain of its executive officers	S-1	333-231838	10.7	5/30/2019
10.4	Form of Amended and Restated Employment Agreement between the Registrant and each of Lance Baldo, MD and Francis T. Lo	S-1	333-231838	10.8	5/30/2019
10.5	Form of Restated Non-Employee Director Change in Control Agreement between the Registrant and each of its non-employee directors	S-1	333-231838	10.9	5/30/2019
10.6	Executive Severance Agreement between the Registrant and Chad Cohen, dated May 1, 2019	S-1	333-231838	10.10	5/30/2019
10.7	Executive Severance Agreement between the Registrant and Lance Baldo, MD, dated April 22, 2019	S-1	333-231838	10.11	5/30/2019
10.8	Executive Severance Agreement between the Registrant and Charles Sang, dated May 1, 2019	S-1	333-231838	10.12	5/30/2019
10.9	Form of Indemnification Agreement between the Registrant and each of its directors and executive officers	S-1	333-231838	10.13	5/30/2019
10.10	Adaptive Biotechnologies Corporation Non-Employee Director Compensation Policy	S-1/A	333-231838	10.14	6/17/2019
10.11	Adaptive Biotechnologies Corporation 2009 Equity Incentive Plan and form of award agreement thereunder	S-1	333-231838	10.15	5/30/2019
10.12	Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and form of award agreement thereunder					X
31.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002					X
31.2	Certification of Principal Financial and Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002					X
32.1*	Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002					X
32.2*	Certification of Principal Financial and Accounting Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002					X


~~101.INS~~	~~XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.~~	X
~~101.SCH~~	~~XBRL Taxonomy Extension Schema Document~~	X
~~101.CAL~~	~~XBRL Taxonomy Extension Calculation Linkbase Document~~	X
~~101.DEF~~	~~XBRL Taxonomy Extension Definition Linkbase Document~~	X
~~101.LAB~~	~~XBRL Taxonomy Extension Label Linkbase Document~~	X
~~101.PRE~~	~~XBRL Taxonomy Extension Presentation Linkbase Document~~	X


†	Portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K promulgated under the Securities Act because the information is not material and would be competitively harmful if publicly disclosed.
*	This certification is deemed not filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

	Adaptive Biotechnologies Corporation

Date: ~~August 13, 2019~~November 3, 2021	By:	/s/ Chad Robins
		Chad Robins
		Chief Executive Officer and Director (Principal Executive Officer)

Date: ~~August 13, 2019~~November 3, 2021	By:	/s/ Chad Cohen
		Chad Cohen
		Chief Financial Officer (Principal Financial ~~and Accounting~~ Officer)

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company